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body,  for  example  breast  or  lung.  The  primary  brain  tumours  form  a  heterogeneous 
group  of  different  tumour  types with  variable  prognoses.  In  adults,  the most  common 
types  of  brain  tumour  are  the  meningiomas  (mainly  benign)  and  gliomas.  In  children, 
although  gliomas  occur,  other  tumours  are  more  frequent  and  include  primitive 
neuroectodermal  tumours (PNETs)  and  medulloblastoma.  Pilocytic  astro‐cytomas  and 
ependymomas, a specific type of glioma, also mainly occur in children.  
Gliomas  
Gliomas  are  a  common  type  of  brain  tumour with  a  slightly  higher  frequency  in males 
compared  to  females,  7.17  and  5.07  per  100,000  in  the  US  (cbtrus.org).  Pathologists 
subdivide gliomas into pilocytic astrocytomas, astrocytomas (A), oligodendrogliomas (O), 
oligoastrocytomas  (OA) and glioblastoma  (GBM). Gliomas can be  further separated  into 
grades  I‐IV  tumours  depending  on  the  number  of  malignant  features  present,  such  as 
anaplasia,  microvascular  proliferation  and  necrosis. (1)  Pilocytic  astrocytomas  (PA)  are 
grade I  tumours;  astrocytomas,  oligodendrogliomas  and  oligoastrocytomas  are  either 
grade II  (low grade) or  III  (anaplastic). GBMs are grade IV. (1) However, the subtyping of 
gliomas based on histological appearance is difficult and there is intraobserver variation. 
Molecular diagnostics may aid  the pathologist  in  classifying gliomas.  For example,  IDH1 




The  survival  rates  of  different  histologies  from  CBTRUS.org,  estimated  from  the  SEER  program.  (PA  – 




The  survival  of  patients  with  a  brain  tumour  is  associated  with  of  the  histological 
diagnosis. The most frequently occurring glioma, GBM, has a median survival of less than 
one  year  and  a  five  years  survival  of  less  than  5%  (cbtrus.org).  Other  gliomas  have  a 
better prognosis, but apart from PAs all subtypes are eventually fatal. (figure 1) 
The  treatment  options  for  low  grade  gliomas  include  surgery,  radiotherapy  and 
chemotherapy. Early  radiation results  in  longer progression  free survival but not overall 
survival. (http://www.oncoline.nl/gliomen). In GBM, which grow faster, surgical resection 




Medulloblastoma  belong  to  the  group  embryonal  brain  tumours.  Apart  from 
medulloblastoma, this group consists of CNS primitive neuroectodermal tumours (PNETs) 
and atypical  teratoid/rhabdoid  tumours. Based on  their histology, medulloblastoma can 
be  further  subdivided  into  classic,  desmoplastic/nodular,  anaplastic,  large  cell 
medulloblastoma and medulloblastoma with extensive nodularity. (1)  
Although  medulloblastoma  most  frequently  occur  in  children  (median  age  of  7  at 
diagnosis),  they can occur  in adults. (5) The vast majority of  the medulloblastoma cases 
are  sporadic,  though  Li‐Fraumeni,  Gorlin  and  Turcot  syndromes  as  well  as  SUFU 
mutations are all  associated with medulloblastoma.  (see table 1) (1, 6, 7)  The  treatment 
options are surgical resection and chemotherapy for children under 3.  In older patients, 
additional  radiotherapy  is  used. (8, 9)  The  prognosis  for  medulloblastoma  patients  is 
better  than  for glioma patients; up  to 70‐80% of  the patients do not have an  incurable 
disease. (8) However,  the side effects of  the  treatment are grave  for  those who survive 




Bont et al  for  an exhaustive  list  and Northcott  et  al  for  a more  recent overview of  the 
novel molecular  developments. (9, 11)  Two well‐established  pathways,  Sonic  Hedgehog 
(SHH)  pathway  and Wnt  pathway,  are  associated with  two  groups  of medulloblastoma 
found  in  expression  profiling. (7, 12, 13)  Alterations  in  these  pathways  consist  of 
mutations,  overexpression  or  deletions.  Examples  of  frequent  alterations  are  PTCH1 
mutations,  Gli1  overexpression  and  Axin1  deletions  and  mutations. (14‐16)  Syndromes 
with mutations  in PTCH and SUFU, both proteins are  involved  in  the SHH pathway, are 
associated with medulloblastoma. Furthermore, although frequent alterations are found 
in  the  Notch  pathways,  these  alterations  do  not  seem  to  be  restricted  to  a  single 
group. (7, 13)  
 
Other  proteins  are  frequently  affected  in medulloblastoma,  such  as mutations  in  TP53, 
members of the IGF signaling pathway, and OTX2. (11, 17, 18) Deletion of genes is rare in 
medulloblastoma,  frequent  deletions  are  PTEN,  PTCH1  and  CDKN2A/B,  the  former  two 









medulloblastomas,  which  can  give  potential  clues  which  genes  are  involved  in 




















This  table  lists  several  syndromes  that  have  been  described  to  be  associated  with  gliomas  and 
medulloblastomas 
 
Of  the  genes  involved  in  hereditary  syndromes  only  TP53  (35%)  and  NF1  (18%)  are 
frequently somatically mutated in gliomas.  In contrast, genes affected by the hereditary 
syndromes in medulloblastoma are also affected in sporadic cases (PCTH1, SUFU, TP53). 
The  remaining genes  found  in hereditary glioma syndromes, only TSC2  and MSH6 were 
found  to  be mutated  in  a  single  sample  in  large  sequencing  studies  of  both GBMs and 




Therefore  the  number  of  patients  affected  may  be  too  low  to  show  an  increased 
frequency of glioma. Nonetheless, these patients display enchondroma like lesions, which 




familial  glioma  syndromes  are  part  of  these  three  core  pathways  or  are  otherwise 
frequently  mutated. (28)  This  suggests  that  additional  core  pathways  are  still  to  be 
uncovered  or  that  new  connections  can  be  found  between  known  genes  and  known 
pathways.  Some  caution  should  be  taken  however  as  these  studies  examined  selected 
hisotlogies such as GBMs (mostly primary GBM) or oligodendrogliomas. 
Somatically mutated  genes  in GBMs  include TP53  (35%), PTEN  (26%), NF1  (18%), EGFR 
(14%), PIK3CA  (10%), PIK3R1  (8%), RB1  (8%)  and  IDH1  (5%). (26, 31)  In  GBMs  genomic 
  11 
amplifications  include  the EGFR,  CDK4  and MDM2  loci  (23%),  deletions  are  common  in 
the CDKN2A, TP53, PTEN and RB1 loci. Fewer genes are mutated in lower grade gliomas. 
The  loss  of  1p  and  19q  is  a  frequent  occurrence  in  oligodendroglioma  and 
oligoastrocytoma, whereas TP53 mutation is more frequently found in astrocytomas. (32) 
Three  frequently mutated  genes  have  been  found  in  oligodendroglioma:  FUBP1  (20%), 
CIC  (83%)  and  IDH1. (27,  31,  33)  Interestingly,  CIC  is  also  overexpressed  in 
medulloblastoma. (34)  In  astrocytomas,  frequently  mutated  genes  include  IDH1,  TP53 
and ATRX. (35) 
EGFR 
The  epidermal  growth  factor  receptor  (EGFR)  belongs  to  a  family  of  epidermal  growth 
factor receptors. Other members of this family include ERBB2 (HER2), ERBB3 (HER3) and 
ERBB4  (HER4). All EGFR  family members are characterised by  two extracullular cysteine 
rich domains and an intracellular tyrosine kinase domain. (36) In order to activate EGFR, a 
ligand  (e.g.  EGF  and  TGF‐α)  has  to  bind  the  extracellular  domain  which  results  in  a 
conformational change allowing dimerisation on a newly exposed interface. (37‐39) This 
results in an activation of the downstream signalling pathways.  
Due  to  its  causal  role  in  cancer,  anti‐EGFR  treatments  have  been  developed.  A  first 
indication of the efficacy of targeted therapies (gefitinib, erlotinib) directed against EGFR 




pulmonary  adenocarcinomas  and  GBMs.  (42)  Although  EGFR  mutations  are  found  in 
many different  cancer  types,  not  all  cancer  types have  the  same  type of mutation.  For 
example, EGFR mutations in lung cancer are small activating mutations (point mutations 




be  a  result  of  different  types  of  genetic  stress  per  cell  type.  Alternatively  the  different 
mutations have different functional consequences.  
IDH1 
Point mutations  in  the  gene  encoding  isocitrate  dehydrogenase  1  (IDH1) were  recently 






are  involved  in  substrate  binding.  The  mutated  protein  has  a  novel  substrate,  α‐
ketogluterate,  and  product,  D‐2‐hydroxyglutarate  (D‐2‐HG).  (45)  D‐2‐HG  is  thought  to 






In  glioma,  the point mutations  in  IDH1  nearly  always occur  at  codon 132  resulting  in  a 
transition  of  an  arginine  to  a  histidine. (46)  IDH1  mutations  are  also  found  in  other 
tumour  types  including  acute  myeloid  leukaemia  (AML),  cholangiocarcinoma  and 
cartilaginous  tumours.  (47‐50)  It  is  interesting  to  note  that  IDH2  mutations  are  also 
frequently found in homologous and conserved codon R172 as well as  in codon R140 in 
AML.  IDH2  mutations  are  rarely  found  in  glioma.  (48,  51)  Although  mutations  are 
restricted to a single hotspot in IDH1, the frequency distribution of the type of mutation 
for  IDH1  is  different  for  glioma  compared  to  AML.  In  AML  the  R132H:R132C  ratio  is 
approximately 1:1 whereas in glioma the ratio is approximately 9:1. (32, 46, 48)  Similar to 
the differential distribution of mutations  in EGFR,  it  remains  to be determined whether 
these  differences  are  due  to  external  factors,  or  if  these  changes  have  a  functional 
consequence.  
Molecular diagnostics in gliomas 
The  number  of molecular markers  is  increasingly  used  in  glioma  diagnostics.  The most 
commons  alterations  known  in  glioma,  used  in  diagnostics,  are  the  codeletion  of 
chromosome  arms  1p  and  19q  (1p/19q),  the methylation  of  the MGMT  promotor  and 
more  recently  IDH1  mutations.  The  1p/19q  alterations  are  most  frequently  found  in 
oligodendrogliomas. Apart from an improved survival, the codeletion of 1p/19q predicts a 
better  response  to  chemotherapy. (4) MGMT  promotor methylation  (the  addition  of  a 
methyl    (‐CH3)  group  to  a  cytosine)  occurs  in  a  subgroup  of  GBMs.  If  methylation  is 





group  various  tumours  together  based  on  unbiased  approaches.  The  determination  of 





display  response  to  therapy. Using  gene  expression  arrays we were  able  to  identify  six 
subgroups  of  gliomas.  In  a  heterogeneous  group  of  gliomas,  consisting  of  different 
histological  subtypes,  our  clustering  method  was  able  to  predict  survival  better  than 
histology.  (53) Other  investigators  have  found different  glioma  subgroups  ranging  from 
three,  four  to  six. (28, 54, 55)  The  differences  in  number  of  groups  depend  on  the 
statistical and molecular  techniques used. The  true value of  these molecular  subgroups 
remains  to be proven  in a  clinical  setting. What we, and others, have  found  is  that  the 
known single markers, for example EGFR amplification, is absent in some groups and very 
frequent  in  others. (56)  This  indicates  that  these  molecular  subgroups  based  on  gene 
expression arrays are also distinguishing between single markers. Similar to adult gliomas, 
different  molecular  subtypes  of  medulloblastoma  have  been  identified  by  expression 
profiling.  (7, 12, 13)  One  of  the  more  commonly  used  molecular  classifications  of 
medulloblastoma  identifies  four major  subtypes WNT,  SHH,  group  C  and  group  D. (12) 
  13 
Another alteration  found  in  tumours  is differential  splicing. This  is  similar  to EGFRvIII  in 




Using  another  technique,  genome  wide  methylation,  one  is  able  to  detect  two  major 
groups, namely CIMP‐ and CIMP+. (57‐59) These groups correlate strongly with survival in 
patients with  a better  survival  for  the  latter. Methylation profiling  can  so  far  subdivide 
gliomas  in  two major  subtypes.  (57) However,  each  tumour  is  unique,  therefore  it  is  a 
matter of time before more groups will be defined. Whether another subgroup of gliomas 
is  useful  in  a  clinical  setting  remains  to  be  demonstrated.  The  initial  future  research 
should  be  focussed  on whether molecular  classification  performs  better  or worse  than 




brain  tumors.  In  chapter one we start with a discovery  study on  subtype  specific  splice 
variants  in medulloblastoma  in  order  to  aid  classification  and  identify  novel  treatment 
targets. In chapters two to five we focus on single causal genetic changes in gliomas. We 
first  give  an  overview  on  the  clinical  and  molecular  implications  of  IDH1  and  IDH2 
mutations  (chapter  two).  In  chapter  three  we  performed  an  in‐depth  analysis  on  the 
prevalence and distribution of mutations in IDH1 in gliomas. Little is known on the cellular 
function of IDH1 mutations. Therefore, in chapter four we performed a functional analysis 
on  this  gene.  The  advent  of  large  datasets  with  mutational  data  reveals  a  novel 
complexity:  different  tumour  types  have  different  mutations  in  the  same  gene.  To 
determine whether the different mutations have different consequences, in chapter five 
we have looked at the molecular and functional consequences of different mutations  in 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Medulloblastoma  is  comprised of  four  distinct molecular  variants: WNT,  SHH, Group 3, 
and Group 4.  We analyzed alternative splicing usage in 14 normal cerebellar samples and 
103 medulloblastomas of known subgroup.  Medulloblastoma samples have a statistically 
significant  increase  in  alternative  splicing  as  compared  to  normal  fetal  cerebella  (2.3‐
times;  P<6.47E‐8).    Splicing  patterns  are  distinct  and  specific  between  molecular 
subgroups.  Unsupervised hierarchical clustering of alternative splicing events accurately 
assigns  medulloblastomas  to  their  correct  subgroup.    Subgroup‐specific  splicing  and 
alternative  promoter  usage  was  most  prevalent  in  Group  3  (19.4%)  and  SHH  (16.2%) 
medulloblastomas,  while  observed  less  frequently  in WNT  (3.2%),  and  Group  4  (9.3%) 
tumors.  Functional annotation of alternatively spliced genes reveals over‐representation 
of  genes  important  for  neuronal  development.    Alternative  splicing  events  in 
medulloblastoma  may  be  regulated  in  part  by  the  correlative  expression  of  antisense 
transcripts,  suggesting  a  possible  mechanism  affecting  subgroup  specific  alternative 
splicing.  Our results identify additional candidate markers for medulloblastoma subgroup 
affiliation,  further  support  the  existence  of  distinct  subgroups  of  the  disease,  and 




Medulloblastoma  (MB)  is  the most  common malignant brain  tumor  in  children  [12,  41, 
45]  and  has  recently  been  demonstrated  to  exhibit  considerable  inter‐tumoral 
heterogeneity  [7,  14].  Recent  publications  have  dissected  medulloblastoma  at  a 
molecular  level  into  four distinct variants – namely WNT, SHH, Group 3 and Group 4[9, 
27,  41,  43,  53].  These  subgroups  differ  in  their  epidemiology,  copy  number  profiles, 
transcriptional networks, mutational spectra, and clinical characteristics [42, 45, 48]. The 




3  or  4  tumors  [13,  43]  with  dismal  overall  survival  and  in  which  the  molecular 
mechanisms driving tumorigenesis remain largely unknown [21]. The optimal mechanism 
for  ‘real  time’  assignment  of  subgroup  affiliation  in  the  setting  of  a  clinical  trial  is  not 
currently  settled.    To  further  understand  the  transcriptional  dissimilarity  between 
subgroups  we  undertook  an  analysis  of  alternative  splicing  and  promoter  use  in 
medulloblastoma. 
 
Alternative  splicing  of  pre‐mRNA  is  a  dynamic mechanism  that  adds  complexity  to  the 
human transcriptome, thereby significantly increasing the diversity of expressed proteins 
[28]. Transcriptional selection of splice sites usage occurs through the processes of: exon 
skipping,  alternative  transcriptional  start  site  usage,  intron  retention,  and  alternative 
polyadenylation  sites,  collectively  referred  to  in  the  current  manuscript  as  alternative 
splicing  [28,  35,  40,  62].  One  or  more  of  these  alternative  splicing  mechanisms  are 
estimated  to  affect  75%  [19]  to  92%  [62]  of  all  genes  in  the  human  genome.  Tight 
regulation  of  normal,  tissue‐specific,  and  developmental  splicing  is  mediated  by  a 
complex network of RNA‐binding proteins that recognize exonic or intronic cis‐regulatory 
elements,  enhancing  or  repressing  inclusion  of  an  exon  in  a  transcript  [19].  Recent 
  19 
evidence  has  also  shown  that  transcription  of  an  overlapping  gene,  encoded  on  the 
opposite DNA strand (antisense transcription) can affect splicing outcomes [57, 58]. 
Alternative splicing has been reported to be “cancer‐specific”, producing protein isoforms 





impact  critical  signaling  and  developmental  pathways  relevant  to  the  pathogenesis  of 
medulloblastoma.  We  undertook  a  comprehensive  investigation  of  alternative  splicing 
across medulloblastoma subgroups  in a  large cohort of primary  tumours  (n=103). Using 
data  from  the  Affymetrix  exon  array  platform,  we  identified  multiple,  recurrent, 
subgroup‐specific  alternative  start  site,  and  exon  dropping  events.  Furthermore,  we 
identified  sense‐antisense  (S‐AS)  transcription,  with  subgroup  specific  expression  of 
antisense transcripts correlating with alternative splicing in medulloblastoma, which may 
represent  a  putative  mechanism  contributing  to  isoform  variability.    Our  data  further 







were  profiled  on  Affymetrix  Genechip  Human  Exon  1.0ST  Arrays.  Samples,  obtained  in 
accordance with Hospital for Sick Children (Toronto, Canada) Research Ethic Board, were 
snap  frozen with  liquid nitrogen at  local host  institutions and stored at  ‐80°C. RNA was 
extracted using  standard TRIzol  (Invitrogen) protocol  and quantification was performed 
using a Nanodrop ND‐1000 Spectrophotometer. The quality of RNA was assessed on an 










Pattern‐based  Correlation  (PAC)  splice  variant  values,  which  represent  the  theoretical 
expression of each probe in relation to gene expression levels, were generated for each 







identify  differentially  expressed  splice  variants  between  molecular  subgroups  of  MBs. 
Differentially expressed splice variants were then further selected based on the degree of 
alternative‐splicing (PAC values > 2 criteria, corresponding to 4‐fold difference in relative 





As  an  alternative  bioinformatic  approach, we  re‐processed  the  data  to  generate  Splice 
Index values for each probe set. First, to filter out probe sets with poor performance or 
low  signal, we  calculated  the median  intensity  across  samples  for  each  of  the  287,189 











across  the  117  samples.  The  top  5%  of  probe  sets  (7464)  with  the  largest  95th‐5th 
percentile  differences  were  selected  as  a  probable  target  of  alternative  splicing.  To 
determine  the number of  alternative  splicing events  across  each  sample,  a  z‐score was 
calculated  for each probe set. Samples with probe sets whose z‐score  fell  two standard 




splice  series  was  generated,  whereas  probe  sets/genes  identified  by  both  algorithms 
were  defined  as  the  consensus  splice  series.  The  collective  splice  series  was  used  to 
identify  subgroup‐specific  alternative  splicing  events  and  hypersplice medulloblastomas 





were  used  for  clustering  analysis.  We  performed  unsupervised  Hierarchical  Clustering 
(HCL) using Pearson’s Correlation as  a distance metric with bootstrapping analysis  (100 
iterations) with all 7464 probe sets using TM4 Microarray SoftwareSuite (MeV v4.6, Dana‐
Farber  Cancer  Institute,  Boston). We  repeated  this  analysis with  the  top  50% of  probe 
sets  (3732)  with  the  highest  standard  deviation,  as  well  as  the  top  25%  of  probe  sets 
(1866),  13.4%  (1000  probe  sets)  and  6.25%  of  probe  sets  (467).  We  identified  the 
strongest  support  for  clustering using 1000 probe  sets which  identified 6  core  clusters, 
composed  of  2  normal  subgroups  (fetal  and  adult  cerebella)  and  4  medulloblastoma 
subgroups.  Non‐negative  matrix  factorization  (NMF)  (Dana‐Farber  Cancer  Institute, 
  21 
Boston) was used as second, unsupervised clustering algorithm. Using both the top 1000 
probe  sets  with  the  highest  standard  deviation,  as  well  as  all  7464  probe  sets,  we 
determined  the  cophenetic  correlation  for  k=2  to  k=8  subgroups.  We  identified  the 




Validation  of  splice  isoforms  was  performed  using  qRT‐PCR.  In  brief,  cDNA  was 
synthesized  from RNA using  Superscript  III  First‐Strand  Synthesis  supermix  (Invitrogen). 
Five‐hundred (500ng) nanograms of RNA was incubated with 2xFirst Strand Reaction mix 
(Invitrogen) and random hexamers (50ng/μL) for 10‐minutes at 25°C and then 1‐hour at 
50°C  prior  to  heat‐inactivation  of  the  enzyme  mixture  at  85°C  for  5‐minutes.  Primers 
designed using Primer Express software were generated targeting regions at the 5’ and 3’ 










Network Gene Ontology  Tool)  [31]  a  Cytoscape plug‐in  [10].  In  brief,  a  hypergeometric 
test was used to assess over represented GO Biological Processes. Benjamini & Hochberg 












Development  Core  Team  2008),  and  were  multiple‐test  corrected  using  the  stringent 
Bonferroni method.  For each S‐AS gene pair, each gene partner was, in turn, analyzed as 









(n=14).  Using  two  independent  bioinformatics  algorithms  –  Splice  Index  (SI)  [37]  and 
Pattern  Based  Correlation  (PAC)  [18]  – we  created  a  ‘collective  splicing  series’  of  9096 
putatively spliced probe sets that map to well annotated exons in 4622 genes (Figure S1a; 
Table  S3).  The majority of  these alternatively  spliced probe  sets  (64%) mapped  to non‐
terminal exons, whereas 15% and 21% of our collective splice series affected probe sets 
which  could  be mapped  to  the  first  or  last  exon,  respectively  (Figure  S2). Most  of  the 
identified alternative  splicing occurred  in medulloblastoma  samples  (79%), while only  a 
minority  (15%) was  specifically  enriched  in  the normal  cerebella  (Figure  1a).  Subgroup‐
specific  splicing  events  were  most  prevalent  in  Group  3  and  SHH  tumors  (19.4%  and 
16.2%  respectively)  and  less  abundant  in  Group  4  (9.3%)  and  WNT  (3.2%) 
medulloblastomas.    Half  (51.9%)  of  all  medulloblastoma‐enriched  splicing  events 
occurred  across  subgroups  in  a mixed population of medulloblastomas  (Figure  1b). We 







adult  cerebella  demonstrates  3.93‐times  higher  median  levels  of  alternative  splicing 
(Figure  1c;  Figure  S3a)  relative  to  the  fetal  cerebella,  however  within  fetal  or  adult 
samples  there  exists  no  direct  correlation  between  age  and  the observed  frequency  of 
alternative splicing (Figure S3b; Figure S3c). 
 
Medulloblastomas  display  on  average  2.3‐times  the  median  levels  present  in  the 
developing fetal cerebella  (P<6.47E‐8), which nonetheless remain 0.59‐times lower than 
those  observed  within  the  developed,  adult  cerebella  (P<1.89E‐2).  A  subgroup‐specific 
analysis  of  medulloblastoma  alternative  splicing  reveals  no  statistically  significant 
differences in the observed number of spliced probe sets across WNT, SHH and Group 3 
tumors whereas Group 4 medulloblastomas possess a  reduced  frequency of alternative 
splicing  (P<2.31E‐2).  Although  medulloblastoma  is  largely  a  pediatric  disease,  adult 
tumors  (age>16)  represent  13.6%  (14/102)  of  our  tumor  cohort.  Pediatric  versus  adult 
medulloblastomas do not display any statistically significant differences (P<4.92E‐1) in the 
observed  frequency of alternative splicing events  (Figure S4a). Furthermore,  there  is no 
correlation between the age of the patient and the frequency of alternative splicing when 
medulloblastoma  is analyzed as a  single disease,  (Figure S4b) however a weak, positive 
trend  towards  increasing  alternative  splicing  with  age  was  observed  in  non‐Group  4 
tumors (Figure S4c).  
The  extensive  intra‐subgroup  variance  in  abundance  of  alternative  spliced  probesets 
permits stratification of medulloblastomas into two broader groups, distinguished by the 
frequency  of  alternative  splicing.    The  first  group,  referred  to  as  “hyperspliced”,  is 
composed of  26  samples with  splicing  frequencies  above  the  75th  percentile  across  all 
medulloblastomas.  The  second  group,  with  splicing  frequencies  comparable  to  those 
present  in  normal  cerebella,  is  referred  as  “non‐hyperspliced”.    Notably,  we  observed 
relative  differences  in  the  distributions  of  Group  3  and  4  subgroups  across  both 






Correlation  (PAC)  algorithms,  across  103  primary  medulloblastoma  and  14  normal  cerebella  samples 
demonstrates strong enrichment patterns in medulloblastoma (79%) with a minority of alternative splicing 
events  restricted  to  the  normal  cerebella  (15%).  (b)  Subgroup  association  of  7509  probe  sets  with 
medulloblastoma‐enriched splicing patterns identifies elevated levels of Group 3 (19.4%, 1454 probe sets) 




per  sample  was  identified,  producing  similar  trends  for  both  algorithms.  Subgroup‐specific  splicing 
patterns  revealed  a  significant  developmental  increase  in  alternative  splicing  from  the  fetal  to  adult 
normal cerebella with a further increase in splicing observed in medulloblastomas. (d) Distribution of the 
molecular  subgroups  of  medulloblastoma  in  hyperspliced  (n=26)  and  non‐hyperspliced  tumors  (n=77) 
reveals  an  increased  frequency  of  WNT  (+6%)  and  Group  3  tumors  (+16%)  in  hyperpliced 
medulloblastomas,  and  a  decreased  frequency  in  Group  4  tumors  (‐20%).  (e)  Subgroup‐specific 
distribution  of  alternative  splicing  per  sample  for  hyperspliced  versus  non‐hyperspliced  tumors. 
Hyperspliced  tumors  demonstrate  a  significant  increased  number  of  alternatively  spliced  exons  across 
each subgroup – ranging from 2.18 (WNT) to 4.97 (Group 3) times higher levels of splicing. (f) Hyperspliced 
medulloblastomas  display  a  significantly  decreased  overall  survival  (P<3.08E‐2)  relative  to  non‐
hyperspliced medulloblastomas. (g) Each molecular subgroup of medulloblastomas demonstrates a trend 
towards  increased mortality  for  hyperspliced  tumors,  with  an  80%  or  greater  increase  in  mortality  for 
WNT, SHH and Group 3 medulloblastomas. 
 24 
relationship  (‐20%)  for  Group  4  medulloblastomas  (Figure  1d).  Hyperspliced 
medulloblastomas demonstrate 2.18 (WNT) to 4.97 (Group 3) times greater frequency of 
median splicing events relative to non‐hyperspliced tumors in the same sub‐group (Figure 
1e).  Strikingly,  there  is  a  significant  decrease  in  the  overall  survival  of  patients  with 
hyperspliced  tumors  (P<3.08E‐2)  (Figure  1f)  with  a  trend  towards  increased  mortality 
across  all  molecular  subgroups  of  the  disease  (Figure  1g).  There  exists  no  significant 
change in the frequency of alternative splicing that occurs in the presence of metastasis 
(Figure S5a), nor is there any change in the incidence of metastasis which correlates with 
the  presence  of  the  hyperspliced  phenotype  (Figure  S5b).  Whether  this  hyperspliced 
phenomena  is a  true biological event with clinical  significance, or an artifact associated 






Through  unsupervised  hierarchical  clustering  (HCL)  of  Splice  Index  (SI)  values, we were 
able  to  recapitulate  the  clustering  pattern  produced  by  gene‐level  transcriptional  data 




7/8)  between  Group  3  and  4 medulloblastomas  –  two molecular  subgroups  previously 
shown to display a higher concordance in copy number and transcriptional profiles.  The 
clustering  pattern  observed  was  highly  robust  (Figure  S6a)  with  >98%  confidence 
associated  with  the  clustering  patterns  of  WNT,  SHH  and  normal  cerebellar  samples 
(Figure S6b). Fetal and adult normal cerebella clustered together with confidence scores 
>81% irrespective of the number of probe sets used to generate the clusters, suggesting 
they  display  a  distinct  alternative  splicing  pattern  from  the  medulloblastoma  samples 
profiled  (Figure  S6a).  There  is  clear  sub‐structure  identified  within  Group  3 
medulloblastomas,  with  half  of  all  Group  3  hyperspliced  tumors  clustering with  a  high 
confidence  (77%)  (Figure  S6b),  further  supporting  the  necessity  of  characterizing  intra‐
subgroup  heterogeneity.  Using  an  independent  and  unsupervised  learning  algorithm, 
Non‐negative Matrix Factorization (NMF), we were able to reproduce our HCL clustering 




from other  SHH  tumors  (Figure  2c).  NMF  produced  an  accuracy  similar  to  that  of  HCL, 
with  93%  (96/103)  of  medulloblastomas  clustering  as  expected.  Importantly,  the 
clustering pattern produced by  alternative  splicing  is  not  driven by  gene expression,  as 
there  is  only  47.2%  (244/516)  overlap  in  the  genes  sets  used  to  generate  stable 







 (a)  Unsupervised  Hierarchical  Clustering  (HCL)  of  the  top  1000  probe  sets  with  the  highest  standard 
deviation  across  Splice  Index  (SI)  values  generates  robust  clustering  of  four  core  medulloblastoma 
subgroups  with  two  normal  cerebella  clusters.  (b)  Non‐Negative Matrix  Factorization  using  the  same 
1000  probe  sets  used  for  HCL  clustering  produces  the  highest  support  (cophenetic  correlation)  for  7 
subgroups. (c) Non‐Negative Matrix Factorization demonstrates 7 core subgroups composed of the adult 
and  fetal  normal  samples,  the  corresponding  four  subgroups  identified  by  HCL,  and  one  additional 







Extensive  Alternative  Splicing  of  Cerebellar  Development  Genes  in  Non‐WNT 
Medulloblastoma. 
To  identify  genes  and  pathways  disproportionately  affected  by  alternative  splicing  we 
performed  Ingenuity  Pathway Analysis  (IPA)  in  a  subgroup  specific manner  (Figure  3a). 
We  identified  pathways  with  known  roles  in  the  pathogenesis  of  medulloblastoma, 
including p53  signaling  (WNT  tumors,  P<1.09E‐2)  [44]  and CREB  signaling  (SHH  tumors; 
P<1.70E‐4)  [46].    Among  medulloblastomas,  TP53  mutations  are  most  common  in  the 
WNT  subgroup  [44].    In  non‐WNT medulloblastomas, we  identified  a  high  incidence  of 
neuronal  development  pathways  affected  by  alternative  splicing.  Of  the  top  ten 
statistically significant pathways, 60% (6/10) in both SHH and Group 3 medulloblastomas, 
and  40%  (4/10)  of  Group  4  tumors,  affected  neuronal  functions  (Figure  S7).  Normal 
cerebella  exhibited  some  overlap  with  these  findings,  however  neuronal  functions  are 






in medulloblastoma.    The  results  complemented our pathway  analysis  demonstrating  a 
strong  enrichment  of  neuronal  networks,  including  nervous  system  development 




2)  [1, 30]. Similarly, alternative splicing events  in SHH and Group 4  tumors comprised a 






molecular  changes  contributing  to  this  phenotype. Using  supervised  clustering, we  first 
identified  the  top 5% of probesets with  the greatest differential  splice  indices between 
the two groups (Figure S9a; Figure S9b). We then examined the molecular function of the 
most  differential  probesets  using  Ingenuity  Pathway Analysis  (IPA).  The majority  of  the 
top  canonical  pathways  differentiating  hyperspliced  from  non‐hyperpsliced  tumours 
affected known cancer signaling pathways (60%, 6/10) (Figure S9c). 
Validation of Subgroup‐Specific Alternative Splicing Events 
We  selected  high  confidence  subgroup  specific  splicing  candidates  from  our  consensus 
splicing series to validate. These events were predominantly found in a single molecular 
subgroup  (>75%),  and  displayed  gross  changes  in  transcript  structure  of  isoforms.  To 
assess subgroup‐specific isoform expression, a transcript ratio was calculated as change in 
3’  versus  5’  expression  levels,  and  normalized  to  fetal  cerebellar  levels.  Exon‐specific 
primers  were  then  designed  to  distinguish  between  3’  and  5’  exon  cassettes.    We 








(a)  Ingenuity  Pathway Analysis  (IPA) of  the  top  ten pathways  affected by  alternative  splicing  across  each 
molecular subgroup of medulloblastoma. Known signaling pathways: such as Tight junction signaling (WNT, 
P<1.49E‐2) and CREB signaling (SHH, P<1.70E‐4) were identified in our analysis as well as an abundance of 
neuronal  pathways  in  non‐WNT medulloblastomas.  (b)  Cytoscape BINGO analysis  of  the  significant Gene 
Ontologies (GO) targeted by alternative splicing in Group 3 tumors, after subtracting events present in the 







promoters  enriched  in  Group  3  and  Group  4  subgroups,  respectively  (Figure  4a).  The 






(a)  Exon array RMA signal  intensity plots of highly  frequent and  subgroup‐specific  alternative  transcripts. 
Alternative  promoter  usage  generates  a  WNT‐specific  3’  isoform  of  INADL,  while  alternative  promoter 
usages in Group 3 and Group 4 tumors produce known isoforms of CHN2 and NBEA, respectively. SNAP25 
demonstrates  subgroup‐specific  expression  of  a  known  exon  cassette  with  Fetal  and  non‐WNT 









evident  in  our  validation  (Figure  4b).  Finally, we  validated  alternative  splicing  targeting 




cerebella and WNT tumors demonstrate higher 5b  levels.   Each of  these splicing events 






51].  Antisense  transcription  can  regulate  splicing  decisions  and  alter  the  balance  of 
isoforms expressed from the sense strand through a variety of mechanisms, such as direct 
transcriptional  interference  based  on  the  physical  consequences  of  convergent 
polymerase complexes (PolII) transcribing both strands of the sense‐antisense gene locus 
[50].  In normal human cells, antisense transcription  is significantly correlated to splicing 




To  determine  whether  antisense  transcription  contributes  to  alternative  splicing  in 
medulloblastoma,  we  analyzed  188  overlapping  gene  pairs  (i.e.  376  genes)  that  are 
encoded  in  opposing  orientations  and  simultaneously  expressed  in  a  given  tumor. 
Alternative  splicing was  predicted  to  occur  in  either  the  sense  or  antisense  gene  in  88 
(46.8%) sense‐antisense partners. We measured the correlation between exon  inclusion 
in  the  sense  genes  (splice  index  (SI)  values;  see  Methods),  and  the  expression  of  the 






validated  [15,  39,  55],  using  independent  molecular  techniques,  demonstrating  the 
validity  and  strength  of  our  approach.  Of  specific  interest  to  us  was NBEA,  previously 
identified  as  alternatively  spliced  in  Group  4 medulloblastomas where  it  is  enriched  in 
isoforms distinguished by an alternative transcriptional start site located mid‐gene (Figure 
4).  Analysis  of  the  antisense‐correlated  splicing  events  identified  the  presence  of  two 
predominant NBEA  isoforms  (Figure  5b).    Expression  of  the  longer  NBEA  isoform  was 
negatively  correlated  (r  =  ‐0.61)  to  the expression of  the antisense gene  (MAB21L1).  In 
contrast, expression of the shorter NBEA isoform, previously identified as upregulated in 
Group C and Group D medulloblastomas (Figure 4b), was positively correlated (r = 0.74) 
to  MAB21L1  expression  (also  up‐regulated  in  Group  D  tumors  (Figure  S11b)).  These 
results  suggest  that  subgroup  specific  expression  of  MAB21L1  contributes  to  the 
regulation of subgroup specific alternative promoter usage of NBEA. 
In the set of 88 S‐AS gene pairs with significant correlations between alternative splicing 














pairs  demonstrating  inverse  relationships  between  sense  strand  exon  inclusion  and  antisense  strand 
transcription.  These  correlations  demonstrate  mixed  medulloblastomas  (C13ORF3‐MRP63)  or  subgroup‐
enriched  (DDX31‐GTF3C4, Group 3 & Group 4) patterns  suggesting S‐AS events may play a critical  role  in 
normal development (SLC26A10‐B4GALNT, Normal CB) and the pathogenesis of medulloblastoma. 
  31 
understand  the  putative  biological  relevance  of  S‐AS  genes  with  antisense‐correlated 
splicing events, we performed pathway analysis, and identified an enrichment of critical 
cellular functions such as cell death, cell cycle regulation and cellular development (Figure 
S11c).    Further  validation  of  the  relationship  between  antisense  transcription  and  the 
regulation  of  alternative  splicing  in  larger  datasets  with  more  comprehensive  AS 






using  two  independent  bioinformatic  approaches.  We  identified  differential  splicing 
across each medulloblastoma subgroup as well as normal fetal and adult cerebella. While 
age‐matched  normal  tissue was  unavailable,  normal  fetal  (20  to  40 weeks  of  age)  and 
adult  (22  to  82  years  of  age)  cerebella were used  as  normal  controls,  representing  the 
developing  and  developed  cerebella.  Based  on  the  distribution  of  alternative  splicing 
events across all  tumors, we were able  to  identify a  ‘hypersliced’ phenotype evident  in 
one‐quarter  of  all  medulloblastomas.  Although  hyperspliced  medulloblastomas  are 
evident across all molecular subgroups, they are significantly under‐represented in Group 
4  tumors.  Notably,  they  display  decreased  overall  survival  and  a  strong  trend  towards 
increased mortality in non‐Group 4 medulloblastomas, indicating that survival trends are 
not    influenced  by  the  over‐representation  of  a  single  aggressive  molecular  variant. 
Hyperspliced tumors do not display any change in the observed frequency of metastatic 
disease  (M+),  nor  do  we  observe  higher  levels  of  alternative  splicing  in  M+  tumors. 
Bioinformatic  analysis  of  probesets  differentiating  hyperspliced  from  non‐hyperspliced 
medulloblastomas identified numerous cancer‐signaling pathways whose instability may, 
in  part,  explain  the  aggressive  nature  of  hyperspliced  tumors.  Clinical  and  biological 
relevance of the observed hyperspliced phenotype awaits its validation on a separate set 
of tumors studied using an independent technology.  
Exon  arrays were designed  to  allow  complementary  analyses  to be performed,  both  at 
the level of gene expression as well as alternative splicing [16]. For the latter purpose, the 
relative  difference  in  exon‐level  probeset  expression  can  be  effectively  interpreted  as 
alternative  splicing,  alternative promoter usage,  and alternative polyadenylation events 
[11,  19,  34,  38].  Although  a  comprehensive  survey  of  transcript  structures  cannot  be 
conducted  using  this  platform,  particularly  in  genes  with  low  expression  values  or  in 
genes  with  numerous  co‐expressed  isoforms,  obvious  and  consistent  events 
corresponding  to  the  above  categories  can  be measured  reliably  and  reproducibly  [16, 
64].  Although  sequencing  technologies  can  explicitly  profile  exon‐exon  junctions,  their 
comparatively prohibitive cost ensures that array‐based approaches are an efficient and 
informative method for rapidly assaying large numbers of tumors, in an effort to address 
the  known  heterogeneity  of  this  disease.  However,  a  complete  catalog  of  alternative 
splicing events remains to be identified through the use of alternative technologies.  
Our  results  are  supported  by  previous  research  demonstrating  a  role  for  alternative 
splicing in medulloblastoma. Most recently, Menghi et al, 2011 [34] examined alternative 
splicing  in  a  modest  cohort  of  14  medulloblastomas  using  the  Splice  Index  algorithm 
which  differentiated  SHH  from  non‐SHH medulloblastomas.  The  authors  identified  174 
 32 
high confidence  splicing events, with an additional 285 probable events. Of  these,  they 
validated  11/14  alternatively  spliced  exons  present  in  a  SHH‐specific  (3/11)  or  in  a 
medulloblastoma‐enriched (8/11) manner. Our analysis  identified 100% of the validated 




We  examined  whether  the  variation  in  alternative  splicing  patterns  reflected  the 
transcriptional  heterogeneity  that  defines  the  four  molecular  subgroups  of 
medulloblastoma  using  two  independent  methods  of  unsupervised  clustering: 
Hierarchical Clustering (HCL) and Non‐negative Matrix Factorization (NMF). HCL produced 
the most  robust  clustering with  four molecular  subgroups of medulloblastoma,  findings 
largely  recapitulated  by  NMF,  which  identified  the  four  core  subgroups  and  one 
additional minor medulloblastoma cluster. The extra NMF cluster composed of three SHH 
medulloblastomas,  two  of  which  are  large  cell  anaplastic  and  hyperspliced,  while  the 
remaining  SHH  tumor  is  classic  and  non‐hyperspliced.  These  tumors  cluster  apart  from 
other  SHH  tumors  in  our  HCl  analysis,  suggesting  they  may  represent  outliers.  As  the 
clustering patterns produced were largely driven by exon from genes  independent from 





prevalent  splicing  events,  found  in  >50‐70%  of  tumors  in  each molecular  variant,  may 
identify  genes  important  in  tumorigenesis,  and may  aid  in  the  identification  of  the  cell 
type  of  origin.    WNT  and  non‐WNT  tumors  display  significantly  different  pathways 
affected  by  alternative  splicing.  Pathway  analysis  of  WNT  medulloblastomas  revealed 
genes  important  to  cerebellar  development  and  medulloblastomas  pathogenesis 
targeting tight  junction signaling  (P<1.49E‐2) and p53 signaling  (P<1.08E‐2)  [44].  In non‐
WNT medulloblastomas there was a high incidence of pathways affecting nervous system 
development  and  differentiation.  Important  neuronal  signaling  pathways  include  CREB 
signaling  in  neurons  (SHH  tumors,  P<1.70E‐4)  and  RAR  activation  (Group  4  tumors, 
P<2.77E‐3), both of which are core or peripheral elements of retinoic acid (RA) signaling. 
Retinoid  treatment  has  been  previously  used  to  induce  differentiation  in 
medulloblastoma  cells  [22].    Furthermore,  our  analysis  has  identified  subgroup‐specific 
pathways  targeting  Roundabout  (ROBO/SLIT)  in  Group  3  tumors.  Deregulation  of 




pairs  expressed  in medulloblastoma  had  a  significant  relationship  between  sense  gene 
splicing  outcomes,  and  expression  of  the  antisense  gene  partner.  An  example  of  this 
relationship is the alternative splicing of NBEA, a neuronal development protein. Our data 
show  that  a  majority  of  Group  4  (91%)  tumors  express  a  truncated  NBEA  isoform 






in  the  regulation  of  subgroup‐specific  alternative  splicing  and  medulloblastoma 
tumorigenesis.  
Our  data  reveals  important  clinical  and  biological  trends  associated  with  alternative 
splicing  in  the  medulloblastoma  transcriptome,  suggests  a  putative  mechanism  for 
subgroup  specific  alternative  splicing,  and  further  highlights  the  transcriptional 
heterogeneity present across, and within, subgroups of medulloblastoma 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The  discovery  of  somatic  mutations  in  the  gene  encoding  isocitrate  dehydrogenase‐1 
(IDH1)  in  glioblastomas  was  remarkable  because  the  enzyme  was  not  previously 
identified with any known oncogenic pathway.  IDH1  is mutated in up to 75% of grade II 
and grade III diffuse gliomas. Apart from acute myeloid leukaemia, other tumour types do 
not  carry  IDH1  mutations.  Mutations  in  a  homologous  gene,  IDH2,  have  also  been 
identified,  although  they  are  much  more  rare.  Although  TP53 mutations  and  1p/19q 
codeletions are mutually exclusive in gliomas, in both of these genotypes IDH1 mutations 
are common.  IDH1 and  IDH2 mutations are early events in the development of gliomas. 
Moreover,  IDH1  and  IDH2  mutations  are  a  major  prognostic  marker  for  overall  and 
progression‐free  survival  in  grade  II–IV  gliomas. Mutated  IDH1  has  an  altered  catalytic 
activity  that  results  in  the  accumulation  of  2‐hydroxyglutarate.  Molecularly,  IDH1  and 
IDH2 mutations are heterozygous, affect only a single codon, and rarely occur together. 
Because IDH1 does not belong to a traditional oncogenic pathway and is specifically and 




In  2008,  a  genome‐wide  sequencing  study  identified  mutations  in  a  gene  encoding 
isocitrate dehydrogenase (IDH1) in 18 (12%) of 149 samples of glioblastoma multiforme.1 
The  mutations  were  most  common  in  young  patients  with  glioblastomas  that  had 
progressed  from  lowgrade gliomas to secondary glioblastoma multiforme. Patients with 
IDH1  mutations  were  also  associated  with  a  longer  survival  than  patients  with 
glioblastomas  without  IDH1 mutations.  Several  papers  have  since  identified  the  IDH1 
mutations  in  other  glioma  subtypes  and  in  various  tumour  types  (table  1).  Functional 
studies2–17  on  IDH1  found  that  IDH1 mutations  in  the  gene  are  highly  glioma  specific. 
Investigations  of  large  numbers  of  other  tumour  types  showed  that  acute  myeloid 
leukaemia  (AML)  was  the  only  cancer  other  with  a  high  incidence  of  IDH1 mutations 
(table  1).  IDH1  is  the  most  commonly  mutated  gene  in  many  types  of  glioma,  with 
incidences  of  up  to  75%  in  grade  II  and  grade  III  glioma  (table  1).  IDH1 mutations  are 
always heterozygous missense mutations that affect aminoacid residue 132 (figure 1) and 





In addition to  IDH1, mutations  in a homologous gene,  IDH2, with a different subcellular 
distribution have been  identified  in  gliomas.  IDH2 mutation  is much  less  common  than 
IDH1  mutation;  the  two  rarely  occur  together,  but  both  seem  to  be  specific  to 
gliomas.5,6,11,24  Inactivating  mutations  in  another  gene,  IDH3B,  have  been  identified  in 
patients with  retinitis pigmentosa, but  they do not  seem  to be associated with  tumour 
formation.25  
Structure and function 
In  human  beings,  five  genes  encode  for  isocitrate  dehydrogenase:  IDH1,  IDH2,  IDH3A, 
IDH3B, and  IDH3G. These genes encode three catalytic  isozymes:  IDH1,  IDH2, and IDH3. 
Both IDH1 and IDH2 function as homodimers whereas IDH3 functions as a heterotetramer 
  39 
composed  of  two  α,  one  β,  and  one  γ  subunit.26  The  function  of  all  isocitrate 
dehydrogenases is to catalyse the oxidative decarboxylation of isocitrate into α‐ 















Astrocytic tumours          
Pilocytic astrocytoma2‐5  1% (0% ‐ 10%)  131/4  0%  21/0 
Pleomorphic 
xanthoastrocytoma2,5 
7% (0% ‐ 14%)  14/1      
Subependymal giant‐cell 
astrocytoma2,5 
0%  14/0      
Diffuse astrocytoma2‐8  74% (0% ‐ 88%)  405/309  0.88% (0% ‐ 7%)  259/4 
Anaplastic astrocytoma2‐9  60% (0% ‐ 78%)  525/324  4% (0.9% ‐ 5%)  301/5 
Glioblastoma          
Primary2‐5,7‐11  5% (3% ‐ 12%)  1153/61  0%  139/0 
Primary pediatric2,5  4% (0% ‐ 7%)  29/1  0%  15/0 
Secondary2‐5,7‐10  75% (50% ‐ 88%)  126/96  0%  11/0 
Giant cell glioblastoma 
multiforme2 
25%  8/2      
Gliosarcoma2  0%  5/0      
Oligodendroglial 
tumours 
        
Olig dendroglioma2‐8  76% (67% ‐ 82%)  366/283  4% (0% ‐ 5%)  188/8 
Anaplastic 
oligodendroglioma2‐8 
67% (49% ‐ 86%)  388/260  5% (0% ‐ 8%)  224/12 
Oli astrocytoma2‐7  80% (50% ‐ 100%)  196/153  1%  76/1 
Anaplastic 
oligoastrocytoma2‐8 
74% (63%‐ 100%)  391/269  5% (0% ‐ 9%)  181/11 
Ependymal  u ours          
Subependymoma2‐8  0%  8/0      
Myxopapillary 
ependymoma2,3 
0%  14/0      
E ‐5  0%  92/0  0%  30/0 
Anaplastic 
ependymoma2,3 
0%  17/0      
Neuronal and mixed 
neuronal‐glial tumours 
        
Ganglioglioma8  37.5%  8/3  0%  8/0 
Anaplastic ganglioglioma7  60%  5/3  0%  5/0 
DNET3  0%  4/0      
Paraganglioma 
(familial)12 
0%  21/0      
P raganglioma 
(sporadic)12 
0%  203/0      
Emb yonal tumours          
Medulloblastoma IV2,3‐5  0%  149/0  0%  55/0 
PNET2,3  17% (0% ‐33%)  17/3      
Tumours of the cranial 
and paraspinal nerves 
        
Schwannoma I2  0%  17/0      
Vestibular Schwannoma3  0%  48/0      
Meningeal tumours          
Meningioma I2,3,11  0%  86/0  0%  14/0 
Atypical meningioma II2  0%  17/0      
Anaplastic meningioma 
III2 
0%  17/0      
Tumours of the sellar 
region 
        
Pituitary adenoma I2  0%  23/0      
Hematological disorders          
Acute leukemia11      0%  166/0 
Acute myelogenous 
leukemia5,13,14 
0% (0% ‐ 9%)  389/21      
Listed are the median and range of the percentages of IDH1 mutations from individual studies. The total 
number  of  mutations  is  a  sum  of  all  samples  from  all  relevant  studies.  The  study  of  Parsons  et  al.  is 
excluded from this table due to partly overlapping sample sets with Yan et al. 
 40 
also differ  in  subcellular  localisation;  IDH1  is  located  in  the  cytoplasm and peroxisomes 







poor  prognosis.35,36  On  the  basis  of  histology,  gliomas  are  classified  into  astrocytic 
tumours  (75%) and oligodendroglial  tumours  (25%). Oligodendroglial  tumours  comprise 
both classic oligodendrogliomas and mixed oligoastrocytic tumours.37 Diffuse gliomas are 














(gliobastoma  multiforme)  depending  on  the  presence  of  malignant  features.  Grade  IV 





in  primary  gliobastoma  multiforme  (table  1).  IDH1  is  among  the  few  genes  that  are 
commonly mutated in grade II and grade III gliomas.39,40 The prevalence of IDH1 mutation 




pilocytic  astrocytomas,  which  are  circumscript  (non‐diffuse)  grade  I  gliomas.42 
Molecularly,  IDH1  mutations  are  associated  with  MGMT  (O⁶‐methylguanine‐DNA 
methyltransferase)  methylation  status,  TP53 mutations,  and  deletions  of  both  1p  and 
19q.3,4,7,22 TP53 mutations and deletions of both 1p and 19q are mutually exclusive and 





















 Histological diagnosis of gliomas  is subject  to substantial  interobserver variation,44  thus 
IDH1 mutation  status  can  provide  an  objective marker  to  identify  the  glioma  subtype. 
IDH1  mutations  are  rare  in  primary  glioblastoma  multiforme  and  are  common  in 
secondary  glioblastoma  multiforme;  therefore,  IDH1  mutation  status  can  distinguish 
between these two subtypes (sensitivity 71∙0–73%, specificity 96%).18 The low incidence 
of  IDH1 mutation  in pilocytic  astrocytomas  also  allows  clinically  relevant differentiation 
between  diffuse  and  pilocytic  astrocytomas  (sensitivity  73–83%,  specificity  100%).18 
Furthermore,  IDH1 mutations  can  have  a  role  in  distinguishing  anaplastic  astrocytomas 
from primary glioblastoma multiforme, or  astrocytomas  from ependymomas.18 Several 












         
Multivariate7*  397  0.4  0.3     
GBM           
Multivariate10†  407        11.3 vs 27.1  
Multivariate20‡  301  0.4  0.4  6.5 vs 16.2   11.2 vs 30.2  
(trend) 
Multivariate15§  159    0.1    8∙4 vs 24.0 
 Univariate
7  183      8.8 vs 55   14 vs 27.4  
Univariate5  129§§        15 vs 31  
Univariate1¶  105§§        13.2 vs 45.6  
Grade III gliomas           
Multivariate21||  318  0.4  0.5     
Univariate7**  121      9.2 vs 37   19.4 vs 81.1  
Anaplastic 
astrocytoma 
         
Univariate5  52        20 vs 65  
Univariate8  21        22 vs 50  
Anaplastic oligodendroglioma and anaplastic astrocytoma     
Multivariate22††  159  0.3  0.2  7.8 vs 50   16  vs not 
reached Grade II gliomas           
Univariate7  100        60.1 vs 150.9  
Progressive low‐grade astrocytoma       













§§Parsons and colleagues1and Yan and colleagues 5 have a partly overlapping sample set. 
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that  those  without  IDH1 mutations,1  with  respect  to  both  overall  survival1,5,7,8,10,15,20–23 
(figure 2) and progression‐free survival.7,20,22 Although patients with an IDH1 mutation are 
generally  younger,  and  that  age  alone  is  an  independent  prognostic  factor  in  gliomas, 
several  studies  have  confirmed  by  multivariate  analyses  the  independent  prognostic 
value  of  IDH1 mutations.7,10,15,20–22  The major  prognostic  importance  of  IDH1 mutation 
status suggests that it should be used as a stratification factor in controlled clinical trials. 
 
Two  studies  have  examined  whether  IDH1  mutation  status  can  predict  response  to 
treatment  in  gliomas.  In  a  group  of  patients  with  dedifferentiated  low‐grade 
astrocytomas  progressive  after  radiotherapy  response  to  temozolomide  did  not  differ 









Several  observations  suggest  a  causal  role  for  IDH1  and  IDH2  in  tumorigenesis.  The 
prevalence and nature of  somatically  acquired mutations does not  suggest  a bystander 
mutation.47  Moreover,  IDH1  and  IDH2 mutations  rarely  occur  together.6  Mutant  IDH1 
causes  an  accumulation  of  2‐hydroxyglutarate,  high  concentrations  of  which  are 
associated  with  brain  tumours.16,48,49  Specific  mutation  types  segregate  into  distinct 
tumour types;6,41 IDH1 mutations are early events in glioma development and have been 
reported to precede both the loss of 1p and 19q and the acquisition of TP53 mutations.3,4 
Furthermore,  the  incidence  of  IDH1 mutations  is  higher  in  grade  II  than  in  grade  III 








histidine  (R132H)  substitution  in  IDH1  or  an  arginine  to  lysine  (R172K)  substitution  in 
IDH2. The remaining IDH1 mutations are, with the exception of R132V (1 of 1630, 0∙1%), 






reported  an  increased  prevalence  of  other  mutation  types  in  specific  histological 
subtypes. In gliomas, R132C mutations seem to be much more common in astrocytomas 
(32  of  591,  5∙4%)  than  in  oligodendrogliomas  (2  of  662,  0∙3%).6,41  Additionally,  all  five 
IDH1‐mutated  astrocytomas  in  patients with  Li‐Fraumeni  syndrome  (ie,  patients with  a 
germline TP53 mutation), had R132C substitutions.53 In AML and in sporadic mutations of 
non‐gliomas,  only  11  of  26  mutations  were  R132H;  R132C  comprise  most  of  the 
remaining mutations.12–14,43 Genetic and epigenetic differences might explain differences 






positions  in the  isozymes.50–52  In  IDH, R132 and R172 are needed for the electrostatic 




of  porcine  R133  (corresponding  to  R172  in  human  IDH2).52  R132  seems  to  be  a 






Results  of  studies  examining  the  functional  consequences  of  IDH1  and  IDH2  mutant 
proteins have shown a strong decrease in the isocitrate‐dependent production of reduced 
NADPH  production.3,5,17  Such  a  decrease  in  enzymatic  activity  suggests  that  both  IDH1 




exerts  a  dominant  negative  effect  on  its  activity.  Because  IDH1  mutations  are 
heterozygous,  both  wild‐type  and  mutant  IDH1  are  expressed  in  a  single  cell.14  When 
dimers  are  formed  between  a mutant  and  a  wild‐type  protein  (heterodimers), mutant 
IDH1  substantially  reduces  the  activity  of  the wild‐type  protein.17  Similar  findings  have 
been  reported  for  IDH2.54 However, many other mutations  generated  in  IDH1 or  IDH2, 
which  are  scattered  across  the  various  domains  of  the  IDH1  and  IDH2  proteins,  also 











dominant negative effect  to be  seen. Additional  experiments on  cell  lysates with  lower 
isocitrate concentrations are needed to confirm the dominant negative effect of mutant 
IDH1.  Second,  a  dominant  negative  tumour‐suppressor  function  is  difficult  to  reconcile 






















An  oncogenic  role  of  IDH1  is  most  compatible  with  the  reported  range  of  mutations; 
hotspot mutations, with  the  exception  of  TP53,  are  commonly  identified  in  oncogenes 
(eg, H‐Ras59, PIK3CA60). This oncogenic role of IDH1 could result from altered substrate 
specificity.  Site  directed mutagenesis  of  the  Esherichia  coli NADP+dependent  isocitrate 
dehydrogenase has  shown  that point mutations  can  result  in  altered  specificity  for  this 
enzyme.61,62  Mutant  IDH1  uses  α‐ketoglutarate  as  a  substrate  to  produce  2‐
hydroxyglutarate  (figure 1).16 Concentrations of 2‐hydroxylglutarate  increase  to over 50 
times that of normal concentrations in IDH1 mutated tumours.16 Mutated IDH1 generates 
the  (R)‐enantiomer of 2‐hydroxyglutarate  (R‐2HG). Accumulation of R‐2HG  is associated 
with  D‐2‐hydroxyglutaric  aciduria,  a  rare  neurometabolic  disorder  with  highly  variable 
phenotypes,  caused  by  a  defect  in  D‐2‐hydroxyglutarate  dehydrogenase.  The  S‐
enantiomer  of  2‐hydroxyglutarate  (S‐2HG)  is  dehydrated  to  α‐ketoglutarate  by  the 
metabolic  repair  enzyme  L‐2‐hydroxyglutarate  dehydrogenase.63  L‐2hydroxyglutaric 
aciduria,  a  hereditary  encephalopathy  due  to  a  defect  in  L‐2‐hydroxyglutarate 
dehydrogenase,  is associated with different brain  tumour  types,  some of which are not 
associated with IDH1 mutations (ependymomas and medulloblastomas).48,49 S‐2HG is not 
a known  intermediate  in any mammalian pathway.63 Moreover, S‐2HG and R‐2HG exert 
different  biological  effects.64  Unlike  L‐2‐hydroxyglutaric  aciduria,  D‐2hydroxyglutaric 




Although  IDH1  mediates  a  reaction  identical  to  that  which  happens  in  the 
tricarboxylicacid  cycle,  IDH1  does  not  play  a  direct  part  in  the  reaction  because  it  is 
localised  in  the  cytosol.  Thus,  IDH1 does not  seem  to mediate  the Warburg  effect  (the 
observation  that  even  under  normoxic  conditions  tumour  cells  preferentially  use 
glycolysis  over  aerobic  respiration).65  Other  tumour‐associated  mutations  in  metabolic 
enzymes  have  been  described  in  hereditary  phaeochromocytoma‐paraganglioma 
syndrome,  hereditary  leio‐myomatosis,  and  renal‐cell  cancer.  Hereditary 
phaeochromocytoma‐paragangliomas  have  dysfunctional  succinate‐dehydrogenase 
complexes,  and  hereditary  leiomyomatosis  and  renal‐cell  cancer  have  dysfunctional 
fumarate hydratase.65,66 Because IDH1 is not part of the tricarboxylic‐acid cycle, the IDH1 
mutations  in  gliomas  are  different  from  the  inactivating  mutations  in  the  metabolic 
pathways of other tumour types. 
 
Little  is  known  about  cytosolic  IDH1  and  its  cellular  function  in  tumours.  Homozygous 
deletions are embryonically lethal in Drosophila melanogaster.67 The biochemical role of 
IDH1 in α‐ketoglutarate and NADPH production allow the cellular function of IDH1 to be 
inferred.  Biochemical  pathways  might  be  affected  by  and  fatty‐acid  biosynthetic 
pathways  (figure  3).68,69  In  changes  in  cellular  α‐ketoglutarate  and  NADPH  nucleicacid 
synthesis,  IDH1  competes  with  the  pentose  concentrations.  The  anabolic  pathways  of 
lipid  synthesis,  phosphate  pathway  for  NADP+  as  an  electron  acceptor.70  cholesterol 
synthesis, and  fatty–acid‐chain elongation Cytosolic  IDH attenuates  the glucose‐induced 
  47 
increase  depend  on  cytoplasmic NADPH.  IDH1  knock‐in mice  in  pyruvate  cycling  in  the 
tricarboxylic‐acid cycle, show substantial changes in lipid metabolism perhaps by affecting 
the concentrations of organic acid,  (eg, hyperlipidaemia,  fatty  liver, and obesity), and  is 
involved in glucose‐stimulated insulin secretion.71 Furthermore, IDH1 activity is regulated 
by cholesterol in pancreatic islet cells.71 α‐Ketoglutarate might affect the activity of IDH 
isozymes  by  end  product  inhibition.72  Finally,  2‐hydroxyglutarate metabolism might  be 
affected as mutant IDH1 converts α‐ketoglutarate to 2‐hydroxyglutarate.16 
 
Several  biochemical  pathways  might  be  affected  by  changes  in  α‐ketoglutarate  and 
NADPH concentrations (figure 3). Overexpression of IDH1 results in increased protection 
against reactive‐oxygen species as well as protection against radiation, whereas inhibition 




stressors,  such  as  protein  excretion  by Helicobacter  pylori  and  heat.78,79  IDH mutations 
might  also  play  a  part  in  the  cellular  migration  and  cellular  response  to  hypoxia.  For 
example,  inhibition of  cytosolic  IDH1 has been  reported  to  increase  lactate production, 
which promotes migration of glioma cells.71,80  
 
α‐ketoglutarate  promotes  the  degradation  of  hypoxiainducible  factor  (HIF)1α,  through 
EGLN (egl nine homologue) prolyl hydroxylases (figure 3). Activation of the HIF pathway 
results  in  the  induction  of  vasucular  endothelial  growth  factor  (VEGF).81  However,  the 
most vascularised gliomas  (primary glioblastoma multiforme) have the  lowest  incidence 
of  IDH1 mutation  among  glioma.  This  finding  suggests  that  decreased  α‐ketoglutarate 
concentrations might  affect  other  HIF  dependent  (energy metabolism)  or  independent 
pathways (EGLN‐related apoptosis).17,65,81–83 Nonetheless, the HIF path way is likely to be 
affected  in  tumours  with  mutations  in  metabolic  enzymes,  such  as  in 
phaeochromocytomaparaganglioma syndrome.84 By contrast with glioma,  IDH1 mutated 
AML  does  not  show  an  increased  expression  of  HIF1α  downstream  target  genes.14,17 
Moreover,  other  biochemical  and  cellular  pathways  are  affected  by mutations  in  IDH1 
and IDH2, and the alternative products generated by mutated IDH1 or IDH2 might affect 




The  incidence of  IDH1 mutation  is very high  in most diffuse gliomas, but not  in primary 
glioblastomas,  and  to  a  lesser  extent  in AML. Mutations  in  the  homologous  IDH2 gene 
also  occur  albeit  with  a  much  lower  incidence  than  IDH1.  These  mutations  are  early 
events in gliomagenesis, and arise both in TP53 mutated astrocytomas and in 1p and 19q 
codeleted oligodendrogliomas. IDH1 is a strong prognostic marker for overall survival and 
progression‐free  survival  in  gliomas,  suggesting  that  future  clinical  trials  might  need 
stratification  by  IDH1  mutation  status.  Molecularly,  IDH1  and  IDH2  mutations  are 
inversely correlated, heterozygous, affect a single codon, and result in different catalytic 
properties. Because of the high mutation frequency, mutated IDH1 could potentially form 
a  good  target  for  new  treatments.  IDH1  is  expressed  at  high  levels  and  seems  to  be 
expressed  in all  tumour cells. The three‐dimensional structure of  the native protein has 
 48 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Mutations  in  the gene encoding  the  isocitrate dehydrogenase 1  gene  (IDH1)  occur  at  a 
high frequency (up to 80%) in many different subtypes of glioma. In this study, we have 
screened  for  IDH1 mutations  in  a  cohort  of  496  gliomas.  IDH1 mutations  were  most 
frequently observed in low grade gliomas with c.395G>A (p.R132H) representing >90% of 
all IDH1 mutations. Interestingly, non‐p.R132H mutations segregate in distinct histological 
and  molecular  subtypes  of  glioma.  Histologically,  they  occur  sporadically  in  classic 
oligodendrogliomas and at significantly higher frequency in other grade II and III gliomas. 
Genetically,  non‐p.R132H mutations  occur  in  tumors  with  TP53 mutation,  are  virtually 
absent  in  tumors with  loss of heterozygosity on 1p and 19q and accumulate  in distinct 
(gene‐expression  profiling  based)  intrinsic molecular  subtypes.  The  IDH1 mutation  type 






The  most  common  type  of  primary  brain  tumor  (~40%)  are  gliomas.  Based  on  their 
histological  appearance,  gliomas  can  be  divided  into  three  distinct  types  of  tumors 
according  to  the  standard WHO  classification  (Kleihues  and  Cavenee  2000):  Astrocytic 
tumors  (75%),  pure  oligodendroglial  tumors  (ODs)  and  mixed  oligoastrocytic  tumors 






gene  (IDH1; MIM#  147700)  in  glioblastomas  (Parsons  et  al.,  2008).  IDH1  catalyzes  the 
oxidative  decarboxylation  of  isocitrate  to  α‐ketoglutarate  and  uses  NADP(+)  as  the 
electron acceptor (Geisbrecht and Gould 1999; Margittai and Banhegyi 2008). Additional 
analysis  showed  that  IDH1 mutations  occur  at  a  very  high  frequency  (up  to  80%)  in  all 
grade  II  and  III  gliomas  (astrocytic,  oligodendrocytic  and  oligoastrocytic)  and  secondary 
GBMs  (Balss  et  al.,  2008;  Parsons,  et  al.,  2008;  Yan  et  al.,  2009;  Dubbink  et  al.,  2009; 
Watanabe et al., 2009a;  Ichimura et al., 2009; Sanson et al., 2009; Sonoda et al., 2009). 
IDH1 mutations  do  not  occur  at  significant  frequencies  in  other  tumor  types,  with  the 
notable  exception  of  acute  myeloid  leukemia  (AML)  (Bleeker  et  al.,  2009;  Yan,  et  al., 
2009;  Mardis  et  al.,  2009).  The  reported  mutations  in  IDH1  all  result  in  a  reduced 
enzymatic activity towards  its native substrate,  isocitrate (Yan, et al., 2009;  Ichimura, et 
al., 2009; Zhao et al., 2009). 
 
Mutations  in  the  IDH1  gene  are  heterozygous  and  virtually  always  affect  only  a  single 
residue  (arginine 132) which  is  replaced by  a histidine  in  approximately  90% of  tumors 
(c.395G>A resulting in p.R132H (Balss, et al., 2008; Ichimura, et al., 2009; Yan, et al., 2009; 
Sanson, et al., 2009). However, non‐p.R132H mutations  in the  IDH1 gene (e.g. p.R132C) 
have  been  reported  to  accumulate  at  higher  frequencies  in  histological  subtypes  of 
glioma (Hartmann et al., 2009), in astrocytomas of Li‐Fraumeni patients (Watanabe et al., 





In  this  study,  we  demonstrate  that  non‐p.R132H  mutations  specifically  accumulate  in 
distinct  histological  subtypes  of  glioma.  Because  histological  classification  of  gliomas  is 
subject to significant interobserver variability (Kros et al., 2007), we also used molecular 
markers (TP53; MIM# 191170), 1p/19q LOH and intrinsic molecular subtypes) to identify 





Glioma  samples  were  collected  from  five  hospitals  in  the  Netherlands  (Erasmus  MC, 
Rotterdam;  UMCU,  Utrecht;  NCI  and  VUMC,  Amsterdam;  RUNMC,  Nijmegen)  from 
patients,  operated  from  1989‐2009.  Use  of  patient  material  was  approved  by  the 
Institutional Review Board. All samples are listed in Supp. Table S1. Histological diagnoses 
were  made  on  formalin‐fixed,  paraffin‐embedded  Haematoxylin  &  Eosin  sections  and 












in‐situ hybridization  (FISH)  (Kouwenhoven et al., 2006),  inferred from genotyping arrays 
or  by  microsatellite  analysis.  Microsatellites  were  amplified  by  PCR  on  20  nanogram 
genomic DNA, using a fluorescently labeled forward primer and a reversed primer. Allelic 
losses  were  statistically  determined  as  described  and  scored  by  two  independent 
researchers  (French  et  al.,  2005).  TP53  (NM_000546.4,  GI:187830767)  status  was 






analysis  using  Cox  Regression.  Differences  between  Kaplan‐Meyer  survival  curves were 
calculated  by  the  Log‐rank  (Mantel‐Cox)  test.  Survival  time  was  defined  as  the  period 









dataset,  a  total  of  246 mutations  in  the  IDH1  gene  were  identified  (49.6%).  The  IDH1 






specifically,  low grade oligodendrogliomas  (79%, n=34/43)  and oligoastrocytomas  (79%, 
n=22/28)  have  a  higher  IDH1  mutation  frequency  then  their  corresponding  grade  III 





described  for  only  a  few  genes  (see  e.g.  (Knowles  2007)).  This  differential  frequency 
indicates  that  low  grade  tumors  can  accumulate  distinct  genetic  changes  and  thus 
represent a different disease entity. Moreover, such differential frequency indicates that 




The  majority  of  mutations  (92.3%)  in  the  IDH1  gene  were  heterozygous  c.395G>A 
missense mutations  that  result  in  an  arginine  to  histidine  substitution  on  position  132 
(p.R132H).  However,  19/246  mutations  (7.7%)  were  non‐p.R132H  mutations:  Single 
nucleotide  changes  that  result  in  different  amino  acid  substitutions  albeit  on  the  same 
position. Similar to reported, c.394C>T (p.R132C) was the second most common mutation 
type  in  our  sample  cohort  and  was  identified  in  nine  gliomas.  Other  non‐p.R132H 
mutations were p.R132S (n=5), p.R132G (n=3), p.R132L (n=1) and p.R132P (n=1). 
 
When  focusing  on  non‐p.R132H  IDH1  mutations  in  our  dataset,  we  observed  that  in 
classical oligodendrogliomas (combined grades II and III), only one out of the total of 98 
IDH1 mutations  (1.0%) was  non‐p.R132H  (Figure  1).  A  significantly  larger  proportion  of 
non‐p.R132H  mutations  was  present  in  oligoastrocytic  tumors  (5/41,  P<0.01)  and  in 
Table 1. The frequency of IDH1 (NM_005896.2, GI:28178824) mutations, LOH on 1p and 19q and 
mutations in TP53 (NM_000564.4, 187830767) in different histological.  
  n  p.R132H  p.R132X  IDH1 
wt 





ODII    43  34  0  9  21  9  13  0  6  37 
ODIII    106  63  1  42  57  31  18  7  18  81 
OAII    28  21  1  6  6  10  12  1  3  24 
OAIII    39  15  4  20  3  23  13  8  2  29 
AII    73  48  6  19  2  53  18  29  18  26 
AIII    32  15  4  13  1  18  13  12  6  14 
GBM   175  31  3  141  10  73  92  27  32  116 









We  aimed  to  confirm  the  differential  distribution  of  non‐p.R132H  mutations  using 
objective  molecular  markers.  We  first  screened  for  combined  LOH  on  1p  and  19q; 





(n=100),  a  mutation  in  the  IDH1  gene  was  detected  in  75  samples  (75%).  In  these  75 
samples, only one non‐p.R132H mutation was  identified  (1.3%, Figure 2). Conversely,  in 
tumors  that  have  retained  1p  and/or  19q  (n=217),  the  proportion  of  non‐p.R132H 
mutations  was  significantly  higher,  13/106  (12.3%,  P<0.01).  Non‐p.R132H  mutations 
therefore segregate in tumors that do not show combined 1p/19q LOH. 
 
We  then  correlated  the  type  of 
IDH1  mutation  to  the  TP53 
mutation  status.  TP53  mutations 
are  frequently  observed  in 
astrocytomas  and  secondary 




In  our  entire  dataset,  TP53 
mutation  status  was  determined 
in  169  samples  (34.1  %).  Of  the 
tumors  with  a  mutation  in  TP53 
(n=84),  a  mutation  in  the  IDH1 
gene was detected  in 65 samples 
(77.4%).  Non‐p.R132H  mutations 
were  identified  in  12 of  these 65 
samples  (17.9%,  Figure  2). 
Conversely,  in  tumors  with  wt 
TP53  (n=85),  the  proportion  of 
non‐p.R132H  mutations  was 
significantly  lower  (3/54)  (5.6%, 
P<0.05).  Non‐p.R132H  mutations 
therefore  accumulate  in  tumors 
with a mutation in the TP53 gene. 
 
Finally,  we  determined  whether  non‐p.R132H  mutations  segregate  in  intrinsic,  gene 
expression based‐, molecular subtypes of glioma.  In a recent study, we  identified seven 







IDH1  mutated  histological  subtypes  of  glioma.  Absolute 
numbers  for  each  subtype  is  stated  in/above  individual  bars. 
For  example,  IDH1  mutations  are  observed  in  54  grade  II 
astrocytomas. Of  these,  six are non‐p.R132H. As can be seen, 
non‐p.R132H  mutations  are  sporadically  observed  in 






cluster  9  (n=1/27,  3.7%)  and more  frequent  in  cluster  17  (5/22,  22.7%,  P=0.05).  Other 
non‐R132  samples were  identified  in  clusters  that  have  relatively  few  IDH1 mutations; 
one in cluster 0 and one in cluster 18 (Gravendeel, et al., 2009). Non‐p.R132H mutations 




The  segregation  of  non‐p.R132H  mutations  into 
distinct  
molecular subtypes of gliomas was validated on a 
recently  described  independent  cohort  of  glioma 
samples  (Ichimura,  et  al.,  2009).  In  this  study,  a 
total  of  119  mutations  in  IDH1  were  identified 
across various histological subtypes, nine of which 
were  non‐p.R132H.  Non‐p.R132H  mutations  are 
clearly  more  prevalent  in  IDH1  mutated 
astrocytomas  (7/45)  compared  to  IDH1  mutated 
oligodendrogliomas  (0/35,  P<0.05).  Furthermore, 
a  significantly  higher  proportion  of  non‐p.R132H 
mutations was observed in tumors with both IDH1 
and  TP53  mutation  (8/65)  compared  to  tumors 
with  wt  TP53  (1/52,  P<0.05).  Finally,  all  non‐
p.R132H mutations were identified in tumors that 
have retained 1p and 19q (9/74 vs. 0/45, P<0.05). 
In  summary,  non‐p.R132H  mutations  are  more 
prevalent  in  IDH1 mutated astrocytomas, gliomas 
with  TP53  mutation  and  gliomas  that  have 




There  are  two  possible  explanations  for  the  differential  distribution  of  non‐p.R132H 
mutations  in  glioma  subtypes.  First,  it  is  possible  that  (epi)genetic  differences between 
tumor types (e.g. differences in DNA repair due to e.g. MGMT (MIM# 156569) promoter 
methylation)  result  in  the  preferential  accumulation  of  distinct  mutations  (see  e.g. 
(Greenman et al., 2007)). For example, MGMT promoter methylation  is associated with 
transition type mutations in TP53 in colorectal cancer and in gliomas (Esteller et al., 2001; 
Nakamura  et  al.,  2001).  Indeed,  a  higher  percentage  of  oligodendroglial  tumors  show 
MGMT  promoter  hypermethylation  compared  to  astrocytic  tumors  (Wick  et  al.,  2009; 
Jeuken et al.,  2007; Yang et al.,  2009). Differences  in  the MGMT promoter methylation 
status  between  glioma  subtypes  may  therefore  explain  the  differential  distribution  of 
non‐p.R132H mutations  in  IDH1. However,  the transition/transversion ratio  in  IDH1 (i.e. 
p.R132H,C/p.R132S,G,L,P)  between  GBMs,  astrocytic  tumors  (AII/III),  oligoastrocytic 
tumors (OAII/III) or oligodendrocytic tumors (ODII/III) is similar (2/32, 5/68, 2/39 and 1/97 
respectively). We also failed to observe a difference in transition/transversion ratio in the 
Figure  2:  The  frequency  of  non‐p.R132H 
mutations  in  IDH1  is  correlated  to 
distinct genetic changes in gliomas. 
 
Non‐p.R132H  mutations  are  more 
prevalent  in  gliomas  that  do  not  show 
combined LOH on 1p and 19q (left) and in 
gliomas  with  a  TP53  mutation  (right). 
Absolute  numbers  for  non‐p.R132H 
mutations/total  number  of  IDH1 
mutations  are  stated  in/above  the 
individual  bars.  *:  P<0.05,  **:  P<0.01, 
Fishers’ exact test. 
  59 
TP53  gene  in  the  respective  histological  subgroups  (14/12,  26/13,  8/1  and  5/2).  The 





A  second  tentative  possibility  is  that  different  mutations  have  different  functional 
properties.  For  example,  non‐p.R132H  mutations  may  show  some  residual  activity 
towards  isocitrate  either  in  cis  (activity  of  the  mutated  enzyme  itself)  or  in  trans  (by 
influencing the activity of the remaining wt enzyme (Zhao, et al., 2009)). Alternatively, a 
recent  study  described  that  mutated  IDH1  is  able  to  convert  α‐ketoglutarate  into 
2¬hydroxyglutarate  (Dang  et  al.,  2009).  Interestingly,  different  IDH1  mutation  types 
showed a differential activity  towards α‐ketoglutarate. Whether  this differential activity 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Objective:  A  high  percentage  of  grade  II  and  III  gliomas  have  mutations  in  the  gene 
encoding isocitrate dehydrogenase (IDH1). This mutation is always a heterozygous point 
mutation  that  affects  the  amino  acid  arginine  at  position  132  and  results  in  loss  of  its 
native  enzymatic  activity  and  gain  of  alternative  enzymatic  activity  (producing  D‐2‐
hydroxyglutarate).  The  objective  of  this  study was  to  investigate  the  cellular  effects  of 
R132H mutations in IDH1. 
 
Methods:  Functional  consequences  of  mutations  were  examined  among  others  using 
Fluorescenceactivated cell sorting, kinome and expression arrays, biochemical assays, and 
intracranial  injections  on  3  different  (glioma)  cell  lines  with  stable  overexpression  of 
IDH1R132H. 
 
Results:  IDH1R132H overexpression  in established glioma cell  lines  in vitro resulted  in a 
marked  decrease  in  proliferation,  decreased  Akt  phosphorylation,  altered morphology, 





Interpretation:  Our  results  demonstrate  that  IDH1R132H  dominantly  reduces 
aggressiveness  of  established  glioma  cell  lines  in  vitro  and  in  vivo.  In  addition,  the 
IDH1R132H‐IDH1wt  heterodimer  has  higher  enzymatic  activity  than  the  IDH1R132H‐
IDH1R132H  homodimer.  Our  observations  in model  systems  of  glioma might  lead  to  a 




Gliomas  are  histologically  classified  into  astrocytic,  oligodendroglial,  and  oligoastrocytic 
tumors.  They are  further  subdivided  into  low grade  (grade  II),  ana‐plastic  (grade  III),  or 
glioblastoma multiforme (grade IV), depending on the presence or absence of malignant 
features.  Mutations  in  the  gene  encoding  isocitrate  dehydrogenase  1  (IDH1)  are  very 
common in all grade II and III gliomas, often occurring at frequencies >70%.1,2 `The IDH1 
mutation frequency  is  inversely correlated to tumor grade,3,4 with the  lowest  frequency 




IDH1  mutations  are  an  early  event  in  tumorigenesis;  they  arise  even  before  TP53 
mutations or  loss of 1p and 19q.7 Patients with  IDH1 mutations are generally  younger, 
and  mutations  are  associated  with  prolonged  survival.3,4,8–11  Mutations  in  the 
homologous  IDH2  gene  were  also  identified,  although  these  occur  at  much  lower 
frequencies in gliomas (0–6%).1,12–15 The only other tumor type in which regular IDH1 and 
IDH2  mutations  are  detected  is  acute  myeloid  leukemia  (AML).16  IDH1  catalyses  the 
oxidative  decarboxylation  of  isocitrate  into  a‐ketoglutarate  (aKG),  thereby  using 
nicotinamide  adenine  dinucleotide  phosphate  (NADP)  as  an  electron  acceptor.17  The 
mutated  IDH1  enzyme  (R132H,  IDH1R132H)  shows  a  strongly  decreased  enzymatic 
  65 








rates  and  alters  the  morphology  and  migration  pattern  of  these  cells.  Although  the 
reduced aggressiveness/proliferation found in our study was identified in established cell 
lines  that  are  different  from  the  in  vivo  growing  tumors,  our  results  may  help  to 






the  green  fluorescent  protein  (GFP)  tag.  U87,  U138,  or  HEK  stable  cell  lines 
overexpressing,  IDH1R132H‐
GFP  pressing  IDH1wt‐GFP, 







sorting  (FACS)  cell  cycle 
analysis,  and  Ki67  staining 
and  apoptosis  assay  were 






using  the  BrdU  In‐Situ  Detection  kit  (BD  Biosciences)  according  to  the  manufacturer’s 
instructions.  Visualization  of  BrdU‐labeled  cells  was  performed  using  biotin‐conjugated 
anti‐BrdU  (1:10)  and  allophycocyanin‐conjugated  streptavidin  (1:400).  Visualization  of 
intracranially  injected  U87  cells  was  performed  using  a  mouse  antivimentin  antibody 
(DAKO, Heverlee, Belgium) and Alexa568‐conjugated antimouse antibody (Invitrogen) at 
1:300  and  1:500  dilutions,  respectively.  Sections  were  counterstained  using  4,6‐
diamidino‐2‐phenylindole (DAKO). 
 
EGFP‐C2‐bio‐IDH1wt  or  EGFP‐C2‐bio‐IDH1R132H  in  combination  with  BirA  were 
transiently  expressed  by  HEK  cells,  and  purified  using  Streptavidin  Dynabeads  M‐280 





























recombinant  enzymes,  of  the 
stable  cell  lines  and  in  primary 
tumors,  were  performed  as 




performed  with  the  U87  stable 
cell  lines.  C.B‐17/Icr‐Hantmhsd‐
Prkdcs  SCID  mice  (Harlan)  were 
stereotactically  injected  with  1  x 
105  tumor  cells  according  to  a 
protocol  previously  described.24 
Tumor  growth  was  measured 




L‐2‐HG  and  D‐2‐HG  were 
measured as described.25 Both  L‐
2‐HG  and  D‐2‐HG  had  no  effect 
on  the  pH  of  the medium  in  the 
concentrations used in this study. 
Stable  U87  and  U138  cell  lines 
were  used  for  mRNA  expression 
analysis on U133 
 
Plus2  arrays  (Affymetrix,  Santa 
Clara, CA). Data were normalized 
using  both  the  MAS5.0 
(Affymetrix)  and  Robust  Multi‐
array  Average  (RMA) 







For  kinome analysis  stable U87  cell  lines were used.  Pepchip  kinomics  arrays  (Pepscan, 
Lelystad, the Netherlands) were hybridized according to the manufacturer’s protocol and 
as described in Parikh et al27 and Sikkema et al28). Pathway analysis was performed using 
the  Ingenuity  Pathways  Analysis  tool  (Ingenuity  Systems,  Mountain  View,  CA).  To 
compare groups, 2‐sided Student t‐tests were used; otherwise, the statistical test used is 







A)  Survival  curve  of  10 mice  injected  with  U87‐IDH1wt‐GFP 
(black line), 10 mice injected with U87‐IDH1R132H‐GFP (dark 
gray line), and 10 mice injected with U87‐GFP (light gray line). 
The  mice  injected  with  U87‐ IDH1R132H‐GFP  have  a 
significantly  longer survival  (p < 0.01); 1 mouse survived >75 
days.  (B)  IVIS  imaging on day 6,  10,  and 12 of mice  injected 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IDH1R132H‐GFP,  IDH1wt‐GFP, or GFP.  In all 3  cell  lines, we observed a  IDH1R132H‐GFP 
decreased  proliferation  rate  of  the  expressing  cell  lines  compared  to  control  (IDH1wt‐
GFPexpressing or GFP‐expressing) cell lines. The decreased proliferation was observed by 
WST  assays  (Fig  1  and  Supporting  Information  Fig  1)  and  confirmed  by  FACS  cell  cycle 
analysis (U87). For example, FACS analysis on exponentially growing cells showed that the 
percentages of cells in S‐phase, G2, or mitosis were lower in IDH1R132H‐GFPIDH1wt‐GFP‐
expressing  cells  than  in  expressing  or GFP‐expressing  cells  (18.3%  vs  22.5%  and  22.4%, 
respectively,  p  <  0.05, Mann‐Whitney U  test).  IDH1R132HGFP‐expressing  cells  also  had 
concurrent  fewer  IDH1wt‐GFP.  Ki67‐positive  cells  compared  to  ‐expressing  cells  (33.6% 
and  45.5%)  and  had  a  reduced  number  of  BrdU‐positive  (proliferating)  cells  in 
IDH1R132HGFP compared to  IDH1wt‐GFP cells  (17.5% vs 19.2%) as determined by FACS 
analysis.  The decreased proliferation was not due  to differences  in  apoptosis. Our data 


















days,  whereas  the  initial  IVIS  measurements  did  detect  tumor  burden  (see  Fig  2  and 
Supporting Information Fig 2).  Immunohistochemistry showed a reduced GFP staining in 
some  of  the  IDH1R132H‐GFP‐induced  but  none  of  the  IDH1wt‐GFP‐induced  tumors, 
indicating  that  IDH1R132H‐GFP  expression  is,  at  least  partially,  lost  in  the  absence  of 
selection  pressure  (Supporting  Information  Fig  3). Mutant  tumor  cells  were  present  as 
indicated by elevated D‐2‐HG levels (see below). The reduced proliferation of IDH1R132H‐
GFP‐expressing  cells  in  vitro  therefore  is  also  apparent  in  vivo  following  intracranial 
injection of IDH1R132H‐GFPexpressing U87 cells. 
 
To  further  investigate  the  cellular  consequences  of  the  IDH1R132H  mutation,  we 









those expressing  IDH1wt‐GFP  in  vivo  (Fig  4).  Such  an  increase  in  infiltrative  foci  in U87 
cells has also been observed by others.29 The IDH1R132H mutation therefore is not only 
associated with a  reduced proliferation rate but also associated with an altered cellular 





overexpressing wild‐type  or mutant  IDH1.15,18  Similar  to  the  findings  reported  by  these 
groups,  our  cell  lines  stably  expressing  IDH1R132HGFP  also  show  reduced  enzymatic 
activity toward isocitrate and increased activity toward αKG compared to IDH1wt‐GFP (Fig 
5 and Supporting Information Figs 4 and 5). Patient‐derived tumors with IDH1 mutations 





Subsequently  we  sought  to  examine 
whether the altered enzymatic activity 
of  IDH1R132H  could  be  recapitulated 
in  a  purified  protein  system with  our 
constructs. For these experiments, we 
generated  constructs  in  which  a 
biotag  was  added  to  the  N‐terminal 
end  of  the  protein.  Biotagged 
constructs  could  then  be  purified 
following  biotinylation  and 
streptavidin‐conjugated  magnetic 
beads.  As  reported  using  extracts  of 
cell  lines,  IDH1bio‐wt‐GFP  had 
enzymatic  activity  toward  isocitrate 
and not toward aKG and vice versa for 
IDH1bio‐R132H‐GFP.  The  activity  was 
dose  dependent  for  both  isocitrate 





protein  system,  the  IDH1bio‐R132H‐
GFP  activity  was  more  active  toward 
aKG in the presence of IDH1biowt‐GFP 
enzyme.  More  αKG  is  converted  in 
these  mixture  experiments,  although 










of  IDH1R132H‐GFP‐expressing  cells  is  a  consequence  of  the  D‐2‐HG  produced  by  the 
mutant enzyme. In our U87 cell lines, D‐2‐HG concentrations are strongly increased, both 
in  cell  pellets  (68μmol/mg  protein)  and  in  the  medium  (55μmol/l)  (Supporting 
Information Fig 7). L‐2‐HG levels were not affected by IDH1R132H‐GFP expression. Similar 
increases were observed  in cell extracts of  intracranially  injected tumors  (26.9μmol/l vs 
1.35μmol/l, p = 0.014, see also Supporting Information Fig 7). 
 
Figure  4: Glioma  cells  expressing mutant  IDH1 have an 
altered migration pattern in vivo. 
 
Intracranially  injected  U87  cell  tumors  expressing 
IDH1R132H‐GFP (bottom panel) are characterized by the 
presence of  infiltrative foci  (arrowheads). Such foci were 
observed  much  less  frequently  in  tumors  expressing 
IDH1wt‐GFP  (top panel).  Red =  vimentin;  blue  =  4,6‐dia‐
midino‐2‐phenylindole;  wt  =  wild  type;  GFP  =  green 
fluorescent  protein. [Color  figure  can  be  viewed  in  the 
online  issue,  which  is  available  at 
www.annalsofneurology.org.] 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The  concentrations  of  D‐2‐HG measured  in  pellets  and media  were  used  to  spike  this 
metabolite  into  the  medium  of  U87  cells  expressing  GFP.  Both  D‐2‐HG  and  L‐2‐HG 
reduced  the proliferation of  these cells  in a dose‐dependent way as measured by FACS 
cell cycle analysis (Fig 6). The percentage of cells in G2‐SM phase was reduced from 20.1% 
to  15.2%  and  7.7%  (p  =  0.018  and  p  =  0.037,  respectively)  by  the  addition  of  3  and 












(A)  Enzymatic  activity  of  purified  enzyme  as measured  by  nicotinamide  adenine  dinucleotide  phosphate 
hydrogen (NADPH) production (expressed by OD340) in the presence of  isocitrate and NADP; IDH1wt‐GFP 
(blue  line) and  IDH1R132H‐GFP (red  line) or a 1:1 mixture of both (purple  line). Green fluorescent protein 
(GFP) (green line) is used as a control. (B) Enzymatic activity as measured by NADPH use in the presence of 
a‐ketoglutarate  of  IDH1wt‐GFP  (blue  line),  IDH1R132H‐GFP  (red  line),  a  1:1  mixture  of  IDH1wt‐GFP  and 
IDH1R132H‐GFP (purple line), and GFP (green line). Error bars represent the standard error of the mean. 
 








It  is  unknown which  oncogenic  pathways  are  affected  by  IDH1R132H  and  D‐2‐HG. We 




































Kinome  profiling  on  our  three 
U87  cell  lines  was  then 
performed  to  further  examine 




GFP‐expressing  cells  and  both 
IDH1wt‐GFP‐expressing  and 
GFP‐expressing  cells  (p  <  0.05) 
(see  Table).  One  of  the  most 
differentially  activated  kinases 





reduced  AKT1  activity  in 
IDH1R132HGFP  expressing  cells 
(Supporting  Information  Fig  9). 




To  our  knowledge,  we  are  the  first  to  describe  the  cellular  effects  of  IDH1R132H‐GFP 
expression  in  established  cell  lines.  Our  data  strongly  indicate  that  IDH1R132HGFP 






It  is possible  that  the reduced proliferation rate  in established glioma cell  lines explains 
why  only  1  tumor  cell  line  expressing  IDH1R132H  has  been  reported,31,32  although 
xenografts  of  glioblastomas  with  IDH1  mutations  have  been  described.5  In  fact,  we 
examined 13 primary cell cultures on serum propagated from IDH1 mutated gliomas. No 
primary  tumor cell  culture bearing  the  IDH1 mutation could be established  from any of 
these gliomas. A reduced presence of  the  IDH1 mutation was already visible  in the first 














U87 GFP + 6 mmol/L D-2HG
U87 GFP + 3 mmol/L D-2HG









It  is  interesting  that  the effects of  IDH1R132H were so apparent although the mutation 
was  introduced  into highly malignant glioma cell  lines. This demonstrates  the dominant 
nature of mutant IDH1 in established cell lines. If mutant IDH1 is also causal for reduced 
proliferation  in  gliomas,  it  might  explain  why  IDH1R132H  is  inversely  correlated  with 
tumor  grade  and  why  IDH1R132H  is  an  independent  favorable  prognostic  marker  in 
glioma  patients.1,3,4  However,  it  is  possible  that  the  effect  of  IDH1R132H  expression 
observed in this study is associated with its expression in highly malignant cell lines that 
have  a  distinct  set  of  genetic  changes  (see,  eg,  Clark  et  al33).  Therefore,  the  effect  of 
















also  Supporting  Information  Fig  7),  whereas  we  demonstrate  that  D‐2‐HG  reduces  the 
proliferation rate of glioma cells. These results appear contradictory to a presumed role 
of D‐2‐HG as an oncometabolite, but it is possible that D‐2‐HG only plays a role in tumor 
initiation.  However,  accumulation  of  D‐2‐HG  is  also  not  associated  with  brain  tumor 

























capacities  and  is  solely  an  inevitable  byproduct.  If  so,  mutated  IDH1  or  IDH2  has 
oncogenic properties not associated with D‐2‐HG. It has been reported that the IDH1 and 
IDH2  mutation  spectra  differ  across  the  various  diseases  (glioma,  AML  and  D‐2‐HG 
aciduria).6,13,36,37  It  is  tempting  to speculate  that  these oncogenic properties vary across 
the different IDH1 and IDH2 mutations. 
 
To  further  elucidate  a  possible  function  of  mutant  IDH1,  we  have  recently  performed 
methylation profiling (Infinium Human methylation 27 arrays [Illumina, San Diego, CA]) on 
a panel of 68 anaplastic oligodendrogliomas and oligoastrocytomas (P.J.F., manuscript in 
preparation).  In  this  study,  the  CpG  island  methylator  phenotype  (CIMP)  was  highly 
correlated with the presence of  IDH1 mutation. These data are  in  line with the recently 
suggested hypothesis  that  IDH1  induces promoter methylation.38 However, not all  IDH1 
mutated tumors are CIMP positive, nor is the effector gene TET2 differentially expressed 
between  IDH1wt‐GFP‐expressing and  IDH1R132H‐GFP‐expressing U87 and U138 cells.  It 










not  tested  the  enzymatic  activity  toward  aKG  of  the  combination  of  IDH1 mutant  and 
wild‐type  enzyme.19,21  The  increased  alternative  enzyme  activity  could  be  explained  by 










In conclusion,  IDH1R132H‐GFP‐expressing cell  lines show a reduced proliferation rate  in 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EGFR‐L858R)  have  differences  in  binding  partners,  downstream  activation  of  gene 
expression, loading into the exosomal compartment, and growth and migration.  
Results: Using biotin pulldown and subsequent mass spectrometry we were able to detect 
mutation  specific  binding  partners  for  EGFR.  Of  these,  the  dedicator  of  cytokinesis  4 
(DOCK4) and UGGT1 associate specifically with EGFRvIII but not with EGFR‐L858R We also 
demonstrate that each mutation induces the expression of a specific set of genes,  likely 
caused  by  the  activation  of  mutation  specific  molecular  pathways.  Finally,  we 
demonstrate  using  stably  expressing  cell  lines  that  EGFRvIII  and  EGFL858R  display 
reduced growth and migration compared to EGFR Wildtype expressing cells.  
Conclusion:  Our  results  indicate  that  there  are  distinct  functional  differences  between 
different EGFR mutations.  This indicates that not all mutations of EGFR can be considered 





on  the  cell  membrane.  EGFR  binds  several  growth  factors  such  as  epidermal  growth 
factor  (EGF)  and  transforming  growth  factor  (TGF)  α.  Growth  factor  binding  results  in 
dimerisation  and  activation  of  a  number  of  different  signal  transduction  pathways 
including  the  RAS‐MAPK/ERK,  JAK‐STAT,  PI3‐K‐AKT‐mTOR  ‐  and  the  JNK  pathways. (1) 
Activation  of  these  EGFR‐mediated  pathways  ultimately  results  in  a  cellular  growth 
and/or differentiation response. (1, 2)  













is  that  each mutation activates  a unique  set of  signal  transduction pathways. Here, we 
have  tested  this  hypothesis  by  screening  for  functional  differences  between  wt‐EGFR, 
EGFR L858R and EGFRvIII. Our results demonstrate that each mutation has a unique set of 
  79 
binding  partners,  induce  expression of  a  different  set  of  genes  and  activate  a  different 
signal  transduction  pathway.  Our  results  suggest  that  EGFR  mutants  cannot  be 
considered identical but should be  investigated as a group of unique but closely related 
proteins. It is possible that different tumour types depend on the pathways activated by 
the  tumor‐type  specific mutations. Better understanding of  the effects of  specific EGFR 




EGFRvIII  and  EGFR  L858R  were  obtained  from  Addgene,  plasmid  20737,  and  plasmid 
11012,  EGFR wildtype was  a  gift  from Ton  van Agthoven.  (12,  13)  The  EGFR  fragments 
were cloned into pcDNA3.1/CT‐GFP‐TOPO (Invitrogen cat no: K4820‐01). A biotin tag was 
added  to  the  construct  at  the 3’  before  the GFP.  These  constructs were used  to  stably 







Cells  were  analyzed  and  sorted  with  a  BD  FACS  Aria  III  (Beckton  Dickinson,  NJ,  USA). 
Live/dead  discrimination  was  performed  using  Hoechst  33258  (Sigma‐Aldrich).  GFP 
fluorescence was detected using a 488 nm laser and emission filters LP520 + BP530/30. 







cells were monitored  for at  least 90 hours and a picture was  taken either every  two or 
three  hours.  Migration  was  done  in  two  separate  experiment  and  the  cells  were 





Constructs  containing  bio‐GFP‐EGFR,  bio‐GFP‐EGFR  L858R  and  bio‐GFP‐EGFRvIII  were 
transfected  into  HEK  cell  lines  using  Polyethylenimine  “Max”  (Polysciences,  Eppelheim, 
Germany).  The  EGFR  wildtype  and  mutants  were  isolated  using  Dynabeads  (Life 
Technologies, Carlsbad, CA, USA) as described previously. (14) The purified proteins were 





The  isolated  protein  was  incubated  with  cell  lysate  from  the  CRL5908  cell  line,  a  lung 
cancer  cell  line  containing  an  EGFR  L858R  mutation.  Using  sodium  dodecyl  sulfate 
polyacrylamide  gel  eletrophoresis  (SDS‐PAGE)  the  samples  were  separated  by  MW. 
Nanoflow LC‐MS/MS analysis was performed essentially as described by van den Berg et 
al.  (15) Analysis of  the mass  spectrometry data was performed  in  two steps. The  initial 






Western  blots  were  performed  essentially  as  described  previously  in  Bralten  et  al.(14) 
Antibodies  used  were  DDX21  (Sigma,  Zwijndrecht,  Nederland,  HPA036592)(1:500); 
UGGT1 (Sigma, Zwijndrecht, Nederland, HPA012761)(1:100), DOCK4 (Sigma, Zwijndrecht, 
Nederland, WH0009732M1)(1:100) ARHGEF5  (Abcam, Cambridge, UK, Ab42695)  (1:100) 











or  biotin‐GFP.  Transfections  were  performed  in  triplicate.  After  FACS  sorting  the  cells 













resulted  in  a  list  of  potential  novel  binding  proteins  for  EGFR  with  some  showing 
differential binding, including DOCK4, UGGT1, MYCBP2, DDX21 and ARHGEF5.  
 





EGFRvIII‐bio‐GFP  respectively.  Similarly  for  UGGT1,  only  peptides  were  identified  by 
pulldown using EGFRvIII‐bio‐GFP  (31 hits) whereas no hits were  found  for EGFR wt‐bio‐






We  then  performed  western  blots  on  independent  biotin  pulldowns  (at  least  two 























DOCK4  colocalises with  EGFR.  Confocal microscopy  pictures  for  immunofluorescent  staining  of  H1975 
and  HELA  cells  against  EGFR  (red),  DOCK4  (green),  DAPI  and  a  merge  picture.  Some  areas  of 















We hypothesized  that  any differential  pathway activation by  the  various EGFR mutants 
would  ultimately  result  in  the  induction  of  a  unique  set  of  genes.   We  have  therefore 
performed  gene  expression  profiling  for HEK  cells  20  hours  after  transient  transfection 
with  EGFR‐bio‐GFP,  EGFRvIII‐  bio‐GFP,  EGFR  L858R‐bio‐GFP,  or  GFP  constructs,  n=3  for 
each  condition.  Analysis  identified  151,  140  and  688  probes  that  were  differentially 
Table 1: Mass spectrometry results for EGFR, DOCK4 and UGGT1. 
  Hits  MASCOT score 
  EGFR  EGFR L858R  EGFRvIII  EGFR  EGFR L858R  EGFRvIII 
EGFR  71  78  52  5239  5717  3754 
DOCK4  54  11  46  2725  536  2136 




    Average survival    Average expression 
    Lower 75  Upper 75  p‐value  EGFR  EGFR L858R  EGFRvIII  eGFP 
ARC  210090_at  4.88  0.93  1.59E‐07  6.76  9.28  6.31  5.75 
C11orf96  227099_s_at  1.20  6.46  7.27E‐09  10.31  12.00  9.49  8.48 
EGFR  201983_s_at  1.58  1.14  0.15  14.27  14.41  14.42  6.11 
EGFR  210984_x_at  1.60  1.05  0.11  10.02  10.81  9.02  5.53 
EGFR  211607_x_at  1.79  1.05  3.20E‐03  9.55  10.38  8.64  5.52 
EGR1  201693_s_at  4.00  1.10  3.10E‐04  8.91  10.93  7.77  6.04 
EGR1  201694_s_at  4.00  1.18  1.32E‐04  11.18  12.64  10.16  8.22 
EGR1  227404_s_at  3.80  1.13  1.78E‐05  9.43  10.70  8.44  6.49 
EGR2  205249_at  3.30  1.18  1.33E‐03  7.59  9.41  6.79  6.11 
EGR3  206115_at  2.32  1.25  0.02  7.07  9.36  6.16  5.57 
ETV5  203349_s_at  3.52  1.64  0.42  8.58  9.33  8.04  5.51 
FOS  209189_at  2.87  1.26  6.37E‐03  7.05  9.09  7.21  5.17 
HSPA6  213418_at  6.82  0.80  1.40E‐09  8.13  9.32  6.74  4.81 
MAFF  36711_at  3.24  1.19  5.74E‐03  8.48  9.77  8.73  6.11 
MAP2K5  211371_at  0.97  1.85  0.04  8.77  9.19  8.78  3.46 
RAP1A  1555339_at  1.61  1.44  0.42  4.92  4.68  7.01  13.44 
RAP1A  1555340_x_at  1.79  1.18  0.14  5.53  5.09  7.35  14.28 
SOCS3  227697_at  6.58  0.86  3.56E‐10  4.90  5.59  9.12  4.53 
TAC1  206552_s_at  1.58  1.31  0.94  6.65  8.21  6.04  4.73 














which  were  EGFR.  To  determine  whether  these  probes  are  also  clinically  relevant,  we 
examined the survival associated with expression of these probes in a dataset containing 
273 gliomas of all histological subtypes.(16) For this exploratory analysis, we have taken 
the 75 highest and  lowest expressing  tumours  for each probe and determined whether 
the  survival  for  these  two  groups  was  statistically  different  (at  p<0.01).  A  total  of  12 
probes were  associated with  survival,  of which  eleven were  negatively  correlated with 
survival and one probe positively correlated with survival.  (see table 2). The 11/20 ratio 





Because  our  results  indicate  that  each  mutation  has  unique  molecular  properties,  we 
determined whether  the various  forms of EGFR also differentially affect cell physiology. 
For  this,  we  created  human  glioma,  HOG,  cells  stably  expressing  EGFR  wt‐bio‐GFP, 





Two  graphs  showing  the  proliferation 
(A)  and  migration  (B)  of  the  stably 
transfected HOG cells with EGFR wt‐bio‐
GFP, EGFRvIII‐bio‐GFP, EGFR L858R‐bio‐
GFPand  bio‐GFP.  The  upper  graph 
displays  the  proliferation  of  the  stably 
transfected  cell  lines  over  a  period  of 
162  hours.  In  our  experiments  we 
consistently  found  that  the  two  EGFR 
mutants,  vIII  and  L858R  grew  slower 
than  GFP.  A  difference  in  proliferation 
between  bio‐EGFRwt  and  bio‐GFP 
expressing cells was not consistent in all 
experiments. The  lower graph display a 
decreased  migration  when  comparing 
the  slope  between  6  and  21  hours  for 
bio‐  EGFRvIII  and  bio‐EGFR‐  L858R, 
compared  to  the bio‐GFP  control  (both 
p<0.001)  or  compared  to  bio‐EGFR‐wt 
cells.  (also  both  P<0.001)  Migration  of 
EGFR‐wt‐bio‐GFP  cells  was  not 
significantly  different  from  bio‐GFP 
controls  (P=0.58). The  lines of EGFRvIII‐
bio‐GFP  and  EGFR  L858R‐bio‐GFP 




GFP  control.  EGFRvIII‐bio‐GFP  and  EGFR  L858R‐bio‐GFP  showed  a  similar  reduction  in 












In  this  paper  we  have  generated  various  mutational  constructs  of  EGFR.  Our  data 




unique  transcriptional  response.  Interestingly,  the expression of many of  these genes  is 
negatively correlated  to patient  survival.    Finally, mutations  in EGFR differentially affect 
cell growth and migration resulting in a decreased growth and migration for EGFRvIII and 
EGFR L858R.  




involved  in  cell migration.  (18) Of  note,  ELMO2 was  also  identified  as  an  EGFR binding 
partner in this study. Furthermore, an ILK/ELMO2 complex is also known to be stimulated 
by  EGFR  resulting  in migration. (19) As  our  experiments  show  that  cell  lines  expressing 
EGFRvIII have a different speed of migration compared to EGFRwt cells, these results are 
in  line  with  the  observation  that  EGFRvIII  and  EGFRwt  differentially  associate  with 
proteins like DOCK4 that are involved in cellular migration.  
DOCK4  also  functions  as  a  scaffold  protein  within  the  Wnt  signaling  pathway  and  is 
essential for activation of this pathway in vivo. (20) There are several reports that provide 
evidence for crosstalk between EGFR and the WNT signaling.  In drosophila for example, 
phyllopod  is  a  downstream  activator  of  EGFR  and  inhibits  the  WNT  signaling. 










EGFRwt  and  control  cells. (24)  It  has  been  reported  that,  in  some  cell  lines  with  high 




an  increased  migration  capacity  compared  to  EGFR  wildtype.  (26,  27)  Our  migration 






of  EGFRvIII.(28,  29)  In  our  experiments  however,  Cbl  proteins  do  not  show  mutation 
specific binding. This difference  is  likely due to the fact  that  (differential) binding to Cbl 
proteins  occurs  only  after  stimulation  with  EGF;  in  these  experiments  we  did  not 
stimulate  cells  with  EGF.  Different  mutations  in  EGFR  also  induce  phosphorylation  of 
different  substrates  and  depend  on  different  downstream  pathways:  EGFRvIII  nuclear 
signalling via STAT5 depends on SRC family kinases, EGFRwt does not  (30, 31). EGFR‐vIII 
but not EGFR‐L858R is imported into the nucleus where it affects DNA repair in response 
to  ionizing  radiation.  (32)  Our  data  expand  on  these  observations  by  performing  a 
detailed characterization of the mutation specific pathways that are affected.  
Mutation  specific  pathway  activation,  such  as  reported  here  for  EGFR,  has  also  been 




and  those  located  in  the  helical  domain,  that  differentially  downstream AKT  signalling. 
(11)  Furthermore,  one  specific  PIK3CA  mutant,  E545K  displays  directional  migration 
whereas another mutant, H1047R, does not. (35)  
In summary, our results show that EGFR and the mutants EGFRvIII and EGFRL858R are not 
identical  when  it  comes  to  binding,  migration,  proliferation  and  gene  expression. 
Mutations within a single protein therefore should not be considered  identical. As each 
mutation  in  EGFR  activates  unique  downstream  pathways,  it  is  possible  that  EGFR 




1.  Alberts  B, Wilson  JH,  Hunt  T. Molecular  biology  of  the  cell.  5th  ed.  New  York:  Garland  Science; 
2008. 
2.  Liu  P,  Cleveland  TEt,  Bouyain  S,  Byrne  PO,  Longo  PA,  Leahy  DJ.  A  single  ligand  is  sufficient  to 
activate EGFR dimers.  Proc Natl Acad Sci U S A.  Jul 3;109(27):10861‐6. 
 86 
3.  van  den  Bent  MJ,  Brandes  AA,  Rampling  R,  Kouwenhoven  MC,  Kros  JM,  Carpentier  AF,  et  al. 
Randomized  phase  II  trial  of  erlotinib  versus  temozolomide  or  carmustine  in  recurrent 
glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009 Mar 10;27(8):1268‐74. 





























17.  Yajnik  V,  Paulding  C,  Sordella  R,  McClatchey  AI,  Saito  M,  Wahrer  DC,  et  al.  DOCK4,  a  GTPase 
activator, is disrupted during tumorigenesis. Cell. 2003 Mar 7;112(5):673‐84. 
18.  Hiramoto‐Yamaki  N,  Takeuchi  S,  Ueda  S,  Harada  K,  Fujimoto  S,  Negishi  M,  et  al.  Ephexin4  and 
EphA2  mediate  cell  migration  through  a  RhoG‐dependent  mechanism.  J  Cell  Biol.    Aug 
9;190(3):461‐77. 
19.  Ho  E,  Dagnino  L.  Emerging  role  of  ILK  and  ELMO2  in  the  integration  of  adhesion  and migration 
pathways. Cell Adh Migr.  May‐Jun;6(3):168‐72. 
20.  Upadhyay  G,  Goessling W,  North  TE,  Xavier  R,  Zon  LI,  Yajnik  V. Molecular  association  between 
beta‐catenin  degradation  complex  and  Rac  guanine  exchange  factor  DOCK4  is  essential  for 
Wnt/beta‐catenin signaling. Oncogene. 2008 Oct 2;27(44):5845‐55. 
21.  Hu  T,  Li  C.  Convergence  between  Wnt‐beta‐catenin  and  EGFR  signaling  in  cancer.  Mol 
Cancer.9:236. 
22.  Ritter  C,  Helenius  A.  Recognition  of  local  glycoprotein misfolding  by  the  ER  folding  sensor UDP‐
glucose:glycoprotein glucosyltransferase. Nat Struct Biol. 2000 Apr;7(4):278‐80. 
23.  Shan  Y,  Eastwood  MP,  Zhang  X,  Kim  ET,  Arkhipov  A,  Dror  RO,  et  al.  Oncogenic  mutations 
counteract  intrinsic  disorder  in  the  EGFR  kinase  and  promote  receptor  dimerization.  Cell.   May 
11;149(4):860‐70. 
24.  Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, et al. Mammalian target of rapamycin 
inhibition  promotes  response  to  epidermal  growth  factor  receptor  kinase  inhibitors  in  PTEN‐
deficient and PTEN‐intact glioblastoma cells. Cancer Res. 2006 Aug 15;66(16):7864‐9. 
25.  Zhao X, Dai W, Zhu H, Zhang Y, Cao L, Ye Q, et al. Epidermal growth factor (EGF) induces apoptosis 






in  oncogenic  transformation  mediated  by  non‐small  cell  lung  cancer‐associated  EGF  receptor 
mutants. Oncogene. 2009 Apr 23;28(16):1821‐32. 
28.  Schmidt  MH,  Furnari  FB,  Cavenee  WK,  Bogler  O.  Epidermal  growth  factor  receptor  signaling 
intensity  determines  intracellular  protein  interactions,  ubiquitination,  and  internalization.  Proc 
Natl Acad Sci U S A. 2003 May 27;100(11):6505‐10. 
29.  Han  W,  Zhang  T,  Yu  H,  Foulke  JG,  Tang  CK.  Hypophosphorylation  of  residue  Y1045  leads  to 
defective downregulation of EGFRvIII. Cancer Biol Ther. 2006 Oct;5(10):1361‐8. 
30.  Chumbalkar  V,  Latha  K,  Hwang  Y,  Maywald  R,  Hawley  L,  Sawaya  R,  et  al.  Analysis  of 
phosphotyrosine  signaling  in  glioblastoma  identifies  STAT5  as  a  novel  downstream  target  of 
DeltaEGFR. J Proteome Res.  Mar 4;10(3):1343‐52. 
















 DOCK4  seems  to  colocalise  with  EGFR  in  tumour  samples.  We  have  looked  at  three  glioblastoma samples,  one  without  EGFR  alterations,  one  with  EGFR  amplification  and  the  last  one  with  EGFR amplification and EGFRvIII.   
Supplementary figure 2: Growth in ZR751 cells after Tamoxifen treatment with or without EGF rescue 
 
Supplementary  figure  2:  In  order  to  determine  if  the  biotin  and  GFP  tag  did  not  interfere  with  the 
functionality of the constructs we transfected wildtype EGFR‐biotin‐GFP in ZR751 cells. After 24 hours they 
were  subjected  to 100mg/ml Tamoxifen. Cells were  incubated either with or without EGF  (concentration 






EGFR  DNM2  SPTLC2  ARL1  SHROOM3 
SOS1  IPO9  UBE3C  CORO1C  BAG5 
DOCK4  ALDH3B1  DDX20  TMOD3  RRAS2 
ARHGEF5  NF1  PIK3CA  AP1G1  PPP2CA 
CBL  VAPA  DNAJC30  S100A7  SC4MOL 
PIK3R1  STAT3  DNAJB14  MAPK1  OSTC 
ELMO2  UPP1  AP1S2  AP3S1  DHRS7B 
AP2A1  EIF2B3  HADHA  OPA1  WDR6 
UBASH3B  NGLY1  TBRG4  SDF2L1  RANGAP1 
IPO5  AP2S1  TUBGCP2  WWOX  CAV1 
AP2B1  NCDN  P14  CBX3  SACM1L 
PKP3  XIAP  VCP  DHCR24  C8orf55 
GRB2  MAP4K5  AP1G2  DHRS2  AP1S1 
ATXN10  LAMB3  XPO5  TMEM43  DNAJC7 
TNPO1  CDC37  TMCO1  TOMM20  EIF2S3 
VAV3  LTN1  VPS28  NPEPPS  ARF6 
IFI16  IPO4  BANF1  STAT1  RPS5 
XPO1  TSG101  NUP93  GNB1  SSR3 
ERRFI1  AP1M1  DNAJC16  NUMB  SNRPE 
SAAL1  HSPB1  ABLIM3  TRPM1  MYADM 
HKDC1  PLK1  CLN6  OCIAD2  SLC39A11 
HEATR3  SUPT16H  RAC1  DCAF7  SERBP1 
AP2M1  GALNT3  DGKA  SSRP1  GRB7 
CRKL  SEC61A1  LAD1  CANX   
CKAP4  FAM125A  ECH1  EIF6   





Probe Set ID  EGFR  EGFRL858R  EGFRvIII  Present 
1555929_s_at  1  1    1 
1556054_at    1    1 
1556347_at    1    1 
1556462_a_at    1    1 
1556543_at    1    1 
1557240_a_at    1    1 
1557270_at    1    1 
1557422_at    1    1 
1557543_at    1    1 
1557738_at    1    1 
1557780_at    1    1 
1558048_x_at  1  1    1 
1558250_s_at    1    1 
1558714_at    1  1  1 
1558739_at    1    1 
1558740_s_at    1    1 
1558854_a_at    1    1 
1558877_at    1    1 
1559156_at    1    1 
1559214_at  1  1  1  1 
1559360_at    1    1 
1559391_s_at    1    1 
1559410_at    1    1 
1559524_at    1    1 
1559723_s_at    1    1 
1559916_a_at    1    1 
1560049_at    1    1 
1560082_at    1    1 
1560271_at    1  1  1 
1560659_at    1    1 
1560661_x_at    1    1 
 90 
1560763_at    1    1 
1561155_at    1    1 
1561195_at    1    1 
1562280_at    1    1 
1563217_at    1    1 
1563494_at    1    1 
1564378_a_at    1    1 
1565689_at  1  1    1 
1565830_at  1  1    1 
1565886_at    1    1 
1566163_at    1    1 
1568408_x_at  1  1  1  1 
1568799_at    1    1 
1569180_at    1    1 
1569181_x_at    1    1 
1569482_at  1  1  1  1 
1570143_at    1    1 
206548_at  1  1    1 
213605_s_at    1    1 
214731_at    1    1 
214862_x_at    1    1 
215592_at  1  1  1  1 
216000_at    1    1 
216683_at    1    1 
217164_at    1    1 
220728_at    1    1 
220915_s_at    1    1 
222227_at  1  1  1  1 
222371_at    1    1 
224254_x_at    1    1 
224549_x_at    1    1 
225193_at    1    1 
225239_at    1  1  1 
226341_at    1    1 
226458_at    1    1 
226848_at    1    1 
227062_at    1    1 
227576_at    1    1 
227663_at    1    1 
227943_at  1  1  1  1 
228216_at    1    1 
228387_at    1    1 
228390_at    1    1 
228465_at    1    1 
228539_at    1    1 
228623_at    1    1 
228919_at    1    1 
229072_at  1      1 
229206_at    1    1 
229243_at    1    1 
229298_at    1    1 
229315_at    1    1 
229366_at    1    1 
229413_s_at      1  1 
229434_at    1    1 
229455_at    1    1 
229470_at    1    1 
229483_at    1    1 
229692_at    1    1 
229869_at    1    1 
229970_at  1  1    1 
230312_at    1    1 
230653_at    1    1 
230657_at  1      1 
230791_at    1    1 
230961_at    1    1 
231165_at    1    1 
231502_at    1    1 
231597_x_at  1  1    1 
231964_at  1  1    1 
232134_at    1    1 
232174_at    1    1 
232257_s_at  1      1 
232338_at    1    1 
  91 
232372_at  1  1  1  1 
232431_at  1  1  1  1 
232453_at    1  1  1 
232511_at    1    1 
232565_at    1    1 
232628_at  1  1    1 
232653_at    1    1 
232726_at    1    1 
232744_x_at    1    1 
232773_at    1    1 
232793_at    1    1 
232889_at    1    1 
233036_at    1    1 
233090_at    1    1 
233152_x_at  1  1    1 
233300_at    1    1 
233518_at    1    1 
233611_at    1    1 
233713_at    1    1 
233908_x_at    1  1  1 
233921_s_at    1  1  1 
234562_x_at    1    1 
234675_x_at    1    1 
234723_x_at    1    1 
234989_at    1    1 
235028_at    1    1 
235224_s_at    1    1 
235274_at    1    1 
235286_at  1  1  1  1 
235456_at  1      1 
235555_at    1  1  1 
235581_at  1      1 
235693_at    1    1 
235701_at    1    1 
235705_at    1    1 
235782_at    1    1 
235786_at  1  1    1 
235803_at    1    1 
235919_at  1  1    1 
235926_at    1    1 
235947_at  1  1    1 
235985_at    1    1 
236032_at    1    1 
236099_at      1  1 
236103_at    1    1 
236170_x_at  1  1    1 
236194_at    1    1 
236220_at    1    1 
236229_at    1    1 
236379_at    1    1 
236404_at    1    1 
236472_at    1    1 
236750_at    1    1 
236924_at    1    1 
237001_at    1    1 
237007_at    1    1 
237269_at  1  1  1  1 
237301_at  1      1 
237310_at    1    1 
237330_at    1    1 
237388_at    1    1 
237483_at    1    1 
237789_at    1    1 
238000_at    1    1 
238595_at    1    1 
238651_at    1    1 
238729_x_at    1    1 
238774_at    1    1 
238883_at    1    1 
238913_at    1    1 
238919_at    1    1 
238932_at  1  1    1 
239049_at    1    1 
239050_s_at    1    1 
 92 
239227_at    1    1 
239347_at    1    1 
239409_at  1  1    1 
239516_at    1    1 
239630_at    1    1 
239673_at    1    1 
239862_at    1    1 
239907_at    1    1 
239934_x_at    1    1 
239946_at  1  1  1  1 
240143_at    1    1 
240170_at    1    1 
240326_at    1    1 
240421_x_at    1    1 
240557_at  1  1    1 
240558_at    1    1 
240721_at  1  1    1 
240798_at  1  1    1 
241506_at    1    1 
241569_at    1    1 
241681_at    1    1 
241773_at    1    1 
241786_at    1    1 
241838_at    1    1 
241853_at    1    1 
241858_at    1    1 
241863_x_at    1    1 
241893_at  1  1  1  1 
242008_at    1    1 
242052_at    1    1 
242110_at    1    1 
242239_at    1    1 
242270_at    1    1 
242273_at  1  1    1 
242310_at    1    1 
242434_at  1  1    1 
242440_at    1    1 
242457_at    1    1 
242471_at    1    1 
242563_at    1    1 
242598_at    1    1 
242671_at    1    1 
242708_at  1  1    1 
242715_at    1    1 
242801_at    1    1 
242824_at    1    1 
242827_x_at    1    1 
242836_at    1    1 
242859_at    1    1 
242894_at    1    1 
242920_at    1    1 
242968_at    1    1 
242989_at    1    1 
243003_at    1    1 
243006_at    1    1 
243008_at    1    1 
243009_at    1    1 
243016_at  1  1    1 
243416_at    1    1 
243431_at    1  1  1 
243509_at  1  1  1  1 
243527_at    1    1 
243561_at    1    1 
243736_at    1    1 
243751_at    1    1 
243768_at    1    1 
243915_at    1    1 
243934_at  1  1    1 
243964_at    1  1  1 
244112_x_at    1    1 
244341_at    1    1 
244383_at    1    1 
244414_at    1    1 
244425_at    1    1 
  93 
244433_at    1    1 
244551_at    1    1 
244610_x_at    1    1 
244726_at    1    1 
244803_at    1    1 
244813_at    1    1 
244845_at    1    1 
228124_at    1    1 
226030_at    1    1 
213808_at    1    1 
230634_x_at    1    1 
225701_at      1  1 
232184_at    1    1 
216550_x_at    1    1 
1556361_s_at    1    1 
1569607_s_at      1  1 
1561079_at    1    1 
220940_at  1  1  1  1 
227337_at    1    1 
201012_at    1    1 
210090_at    1    1 
205239_at    1    1 
1553349_at    1    1 
220468_at    1    1 
210718_s_at    1    1 
242727_at    1    1 
219996_at    1    1 
219918_s_at  1  1    1 
1554980_a_at    1  1  1 
202672_s_at    1  1  1 
205704_s_at    1    1 
1553959_a_at  1  1    1 
1559078_at    1    1 
1555372_at    1    1 
203140_at    1    1 
1554443_s_at    1    1 
201170_s_at    1    1 
225144_at    1    1 
207186_s_at    1    1 
230056_at    1    1 
238545_at  1  1  1  1 
238890_at    1    1 
209183_s_at      1  1 
1559265_at    1    1 
1559266_s_at    1    1 
238593_at    1    1 
227099_s_at  1  1  1  1 
218723_s_at    1    1 
215087_at  1  1    1 
208109_s_at  1  1    1 
239208_s_at    1    1 
220770_s_at    1    1 
212913_at    1    1 
239297_at  1      1 
231270_at    1  1  1 
239106_at    1    1 
1554327_a_at    1    1 
240983_s_at    1    1 
219342_at    1    1 
238549_at    1    1 
239014_at    1    1 
232362_at  1  1    1 
205899_at    1    1 
204490_s_at    1    1 
203252_at  1  1  1  1 
202284_s_at    1    1 
228482_at      1  1 
212501_at  1  1  1  1 
204203_at    1  1  1 
205046_at  1  1  1  1 
205250_s_at    1    1 
224150_s_at    1    1 
219270_at  1  1  1  1 
1565951_s_at    1    1 
 94 
226350_at    1    1 
239436_at    1    1 
242492_at    1    1 
223500_at    1    1 
204573_at    1    1 
225557_at    1  1  1 
209101_at    1    1 
206085_s_at    1  1  1 
217127_at  1  1  1  1 
201289_at    1    1 
210764_s_at    1    1 
209158_s_at    1    1 
1562209_at  1      1 
1554049_s_at    1  1  1 
242428_at    1    1 
209383_at  1  1  1  1 
225434_at    1    1 
204383_at    1    1 
239730_at  1  1  1  1 
32032_at    1    1 
242539_at  1  1    1 
230229_at    1    1 
203791_at    1    1 
200664_s_at  1  1    1 
200666_s_at  1  1    1 
223054_at    1  1  1 
1554462_a_at    1  1  1 
202842_s_at    1  1  1 
202843_at  1  1  1  1 
1558080_s_at      1  1 
214844_s_at    1    1 
205493_s_at    1    1 
232098_at    1    1 
208891_at  1  1  1  1 
208892_s_at  1  1  1  1 
208893_s_at  1  1  1  1 
228116_at    1    1 
201983_s_at  1  1  1  1 
210984_x_at  1  1  1  1 
211607_x_at  1  1  1  1 
201693_s_at  1  1  1  1 
201694_s_at  1  1  1  1 
227404_s_at  1  1  1  1 
205249_at  1  1    1 
206115_at  1  1    1 
207768_at    1    1 
205222_at    1    1 
214314_s_at    1    1 
227491_at    1    1 
203499_at    1    1 
227449_at    1    1 
206852_at    1    1 
229288_at    1    1 
238533_at    1    1 
241252_at    1    1 
221911_at  1  1    1 
211603_s_at    1    1 
203348_s_at  1  1  1  1 
203349_s_at  1  1  1  1 
216375_s_at    1    1 
230102_at  1  1  1  1 
204363_at    1    1 
229512_at    1    1 
217966_s_at    1    1 
217967_s_at    1  1  1 
223791_at    1    1 
219895_at    1    1 
228587_at    1    1 
225667_s_at    1    1 
236976_at    1    1 
244071_at    1  1  1 
236994_at    1    1 
228427_at      1  1 
219910_at      1  1 
  95 
242828_at    1    1 
239005_at    1    1 
229246_at    1    1 
210414_at    1    1 
209189_at  1  1  1  1 
202768_at    1    1 
218880_at    1  1  1 
205140_at    1    1 
230964_at    1    1 
206109_at    1  1  1 
227499_at    1    1 
239082_at    1    1 
213524_s_at    1    1 
207574_s_at    1    1 
209304_x_at    1    1 
209305_s_at    1    1 
213560_at    1    1 
221577_x_at  1  1  1  1 
204472_at    1    1 
1560133_at    1    1 
222710_at      1  1 
213212_x_at    1    1 
208798_x_at    1    1 
208311_at    1    1 
210999_s_at    1    1 
235405_at    1    1 
215470_at    1    1 
226606_s_at  1  1  1  1 
227235_at  1  1    1 
209315_at    1    1 
232975_at    1    1 
225989_at    1    1 
217168_s_at  1  1  1  1 
221606_s_at    1    1 
207165_at    1    1 
209709_s_at    1    1 
225107_at    1    1 
231786_at    1    1 
238808_at    1    1 
214457_at  1  1  1  1 
210189_at    1    1 
211936_at  1  1  1  1 
230031_at  1  1  1  1 
117_at  1  1    1 
213418_at  1  1  1  1 
221667_s_at    1    1 
200825_s_at  1  1  1  1 
202081_at    1    1 
201631_s_at    1    1 
203153_at    1    1 
219174_at    1    1 
210095_s_at    1    1 
204912_at    1    1 
206924_at    1    1 
207160_at    1    1 
207375_s_at    1    1 
222062_at    1    1 
214705_at    1    1 
210587_at  1  1  1  1 
202794_at    1    1 
237056_at      1  1 
201625_s_at    1    1 
220225_at    1    1 
232352_at    1    1 
203337_x_at  1  1  1  1 
240037_at    1    1 
201473_at    1    1 
223584_s_at    1    1 
223412_at    1    1 
219615_s_at    1    1 
212188_at    1    1 
212192_at    1    1 
1555897_at    1    1 
213146_at    1    1 
 96 
214295_at    1    1 
215268_at    1    1 
212779_at    1    1 
204444_at    1    1 
228377_at    1    1 
210634_at    1    1 
232297_at    1    1 
1561206_at    1    1 
201596_x_at    1    1 
1556616_a_at  1  1  1  1 
227074_at    1    1 
233512_at    1    1 
1554609_at    1    1 
215287_at    1    1 
241535_at    1    1 
222947_at    1    1 
240382_at    1    1 
221973_at  1  1  1  1 
221919_at    1    1 
240908_at    1    1 
239017_at  1  1    1 
213703_at  1  1  1  1 
220609_at    1    1 
1557113_at    1    1 
229007_at    1    1 
1556064_at    1    1 
232182_at  1  1    1 
65588_at    1    1 
236181_at  1  1    1 
242329_at    1  1  1 
1558688_at  1  1  1  1 
228908_s_at    1    1 
1557765_at  1  1  1  1 
1558404_at      1  1 
239343_at    1    1 
224686_x_at    1    1 
1559580_at    1    1 
241792_x_at    1    1 
242389_at    1    1 
223687_s_at    1    1 
228841_at    1    1 
240344_x_at    1    1 
226748_at    1    1 
205193_at  1  1  1  1 
36711_at  1  1  1  1 
226206_at    1    1 
224558_s_at    1    1 
202655_at  1  1  1  1 
211371_at  1  1  1  1 
205192_at    1    1 
205027_s_at    1    1 
235421_at    1    1 
213132_s_at    1    1 
200798_x_at    1    1 
225955_at    1    1 
232194_at    1    1 
225316_at  1  1    1 
232568_at    1    1 
210694_s_at    1    1 
1569652_at    1    1 
224873_s_at    1    1 
220346_at  1      1 
228846_at    1    1 
215318_at    1    1 
228529_at    1    1 
212803_at    1    1 
221207_s_at  1  1    1 
242121_at    1    1 
225786_at    1    1 
200632_s_at    1    1 
224565_at  1  1  1  1 
224566_at    1  1  1 
226103_at  1  1    1 
204109_s_at  1  1    1 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228933_at    1    1 
221348_at    1    1 
213479_at    1    1 
206645_s_at    1    1 
229422_at    1    1 
1557071_s_at    1    1 
223535_at    1    1 
224938_at    1    1 
205728_at    1    1 
213825_at  1  1  1  1 
1554008_at      1  1 
1564494_s_at    1    1 
210941_at  1  1  1  1 
228640_at  1  1    1 
203378_at  1      1 
226119_at    1    1 
229287_at    1    1 
222380_s_at    1    1 
214582_at    1    1 
222317_at  1  1    1 
208658_at      1  1 
211048_s_at  1    1  1 
241801_at    1    1 
217996_at    1    1 
217997_at    1    1 
209803_s_at    1    1 
202924_s_at    1    1 
1560556_a_at    1    1 
233241_at    1    1 
213677_s_at    1    1 
223568_s_at      1  1 
226150_at  1  1  1  1 
226384_at      1  1 
228108_at    1    1 
202014_at    1  1  1 
37028_at    1  1  1 
1555783_x_at    1    1 
235987_at    1    1 
1552348_at  1  1  1  1 
211756_at    1    1 
238695_s_at    1  1  1 
208393_s_at    1    1 
209349_at    1    1 
1555339_at  1  1  1  1 
1555340_x_at  1  1  1  1 
1557432_at    1    1 
1553185_at    1    1 
1553186_x_at    1    1 
230563_at    1    1 
205178_s_at    1    1 
212783_at    1    1 
228455_at  1  1  1  1 
219754_at    1    1 
214409_at  1      1 
234297_at  1  1    1 
1553713_a_at    1    1 
1570253_a_at  1  1  1  1 
223169_s_at      1  1 
1556088_at    1    1 
213959_s_at  1      1 
230469_at  1  1    1 
219957_at    1    1 
204351_at      1  1 
236487_at  1  1    1 
218681_s_at  1  1  1  1 
202375_at  1    1  1 
222385_x_at    1    1 
215028_at    1    1 
226492_at    1    1 
202319_at  1      1 
223394_at    1    1 
223195_s_at    1    1 
223196_s_at    1  1  1 
222310_at    1    1 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212177_at    1    1 
212179_at    1    1 
1570507_at    1    1 
242963_at    1    1 
230165_at  1  1    1 
235425_at    1    1 
203320_at    1    1 
226673_at      1  1 
205234_at    1  1  1 
209610_s_at  1  1  1  1 
212810_s_at  1  1  1  1 
212811_x_at  1  1  1  1 
200924_s_at    1    1 
212944_at    1  1  1 
1569940_at    1    1 
206566_at    1    1 
212290_at    1    1 
212292_at    1    1 
212295_s_at    1    1 
207528_s_at    1    1 
235518_at    1    1 
204368_at    1    1 
1553055_a_at      1  1 
1557078_at  1  1  1  1 
207069_s_at    1    1 
215623_x_at  1      1 
203372_s_at      1  1 
203373_at      1  1 
206359_at      1  1 
227697_at    1  1  1 
225728_at    1    1 
227426_at    1    1 
230337_at    1    1 
204915_s_at    1    1 
226913_s_at    1    1 
232529_at  1  1    1 
204011_at    1    1 
221489_s_at  1  1    1 
227288_at    1    1 
223821_s_at    1    1 
223822_at    1    1 
206552_s_at  1  1  1  1 
1569566_at    1    1 
238067_at    1    1 
226126_at    1    1 
208089_s_at    1    1 
232692_at    1    1 
209277_at    1    1 
209278_s_at  1  1    1 
209651_at    1    1 
242163_at    1    1 
201666_at    1    1 
212194_s_at    1    1 
235798_at    1    1 
219253_at    1    1 
236219_at  1      1 
222690_s_at      1  1 
218368_s_at    1    1 
207536_s_at    1  1  1 
206907_at    1    1 
238520_at    1    1 
202241_at    1    1 
1555788_a_at  1  1  1  1 
218145_at  1  1  1  1 
210705_s_at  1  1  1  1 
221897_at    1    1 
230280_at    1    1 
227236_at    1    1 
215898_at    1    1 
203234_at    1    1 
212980_at    1    1 
233595_at    1    1 
213686_at    1    1 
227987_at    1    1 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227988_s_at    1    1 
235023_at    1    1 
1557132_at    1    1 
1554140_at  1      1 
1554141_s_at  1      1 
229816_at  1      1 
213425_at    1    1 
200670_at  1  1  1  1 
224590_at    1    1 
231211_s_at  1  1  1  1 
1554036_at    1    1 
1554037_a_at    1    1 
228715_at    1    1 
215427_s_at    1  1  1 
235133_at  1  1    1 
229240_at    1    1 
243835_at    1    1 
222186_at    1    1 
201531_at    1    1 
227796_at    1    1 
235408_x_at    1    1 
238631_at    1    1 
228157_at    1    1 
228185_at    1    1 
231864_at    1    1 
228927_at    1    1 
213124_at    1  1  1 
220444_at    1    1 
204175_at    1    1 
227822_at    1    1 
235079_at    1    1 
221645_s_at    1    1 
1569157_s_at      1  1 
226808_at    1    1 
222814_s_at    1  1  1 
1562988_at  1  1  1  1 













how  they  functionally  contribute  to  tumourigenesis.  In  chapter  two we have described 
IDH1 mutations in detail and compared them to known information in the literature. (1) 
In chapter three we performed and  in‐depth analysis of  IDH1 mutations examining how 





Brain  tumors  are  a  complex  heterogeneous  group  of  diseases.  Therefore,  researchers 
have  focused on histologically or molecularly defined  subgroups  to determine  subtype‐
specific  driver  mutations,  mutually  exclusive  mutations  or  whether  specific  mutations 
occur  together.  One  of  the  drawbacks  of  using  molecular  subgroups  is  the  lack  of 
consensus definitions, unlike the WHO classification for histology. For example, in gliomas 
there  are  currently  four  commonly  used  gene‐expression  based  classifications  and  for 
medulloblastomas  there  are  three,  although  in  medulloblastoma  one  consensus 
classification  is  currently  agreed  on.  (4‐10)  Also,  different  molecular  methods  for 
classification do not yield  identical  results. For example,  the subgroups  found by mRNA 
profiling  in  glioma  have  only  partial  overlap  with  subgroups  found  using  methylation 
profiling.  Therefore  it  is unlikely  that a  single  classification will  hold  for every question. 
Potentially  different,  or  novel,  classifications  are  required  for  different  situations,  for 
example when identifying predictive response markers.  
 
In  chapter  one  we  describe  the  presence  of  subtype‐specific  splice  variants  in 
medulloblastomas. The functional relevance of these specific splice variants remains to be 
determined  but  if  they  are  required  for  tumor  growth  they  can  form  novel  targets  for 
treatment. (11, 12) Although the frequency of any alteration in a tumour is not a marker 
for  impact  on  the  tumour,  it  does  indicate  relevance  for  the  tumour.  A  frequently 
mutated  gene  indicates  that  this  specific  alteration  is  essential  for  a  tumour  type; 
however,  a  low  frequency  does  not  indicate  a  low  impact  on  the  tumour.  In  addition, 
since  a  tumour  evolves,  any  alteration  can  be  used  to  mark  progression.  The  splice 
variants that we have identified in medulloblastomas occur in multiple samples, therefore 
they may  be  important  for  the  disease.  To  determine  importance,  causality  in  e.g.  cell 
growth, migration or gene expression assays is required.  
Another question is whether we should focus our future research on single events, such 
as  alternatively  spliced  genes,  or  rather  on  the  interaction  between  commonly  found 
alterations.  Since  a  tumour  is  a  complex  interaction  between  multiple  mutations  it 
remains to be seen whether an increase in commonly used readout parameters will hold 
true  in  the  interaction.  For  example,  the  different  mutations  differentially  affect 
migration of cancer cells. It remains to be determined what the net effect is when these 
mutations co‐occur in a single cancer cell. Classical molecular biological techniques, such 




High  throughput  screening,  such  as  performed  in  chapter  one,  has  so  far  giving  us  a 
limited number of that are mutated at high frequency mutations in glioma: IDH1 in 2008 
in  low grade glioma and FUBP1 and CIC  in oligodendroglioma in 2011. (13, 14) Our own 
findings  with  exon  arrays  did  not  identify  frequent  novel  mutations. (15,  16)  Novel 
techniques  give  a  wealth  of  publically  available  information;  optimal  usage  of  this 
information will be a challenge. Nonetheless,  it  is a potential treasure trove for a better 
understanding  of  the  tumours.  Using  clusters  of  genes  mutated  together  in  a  single 
tumour, might  give  a  better  understanding  of  how mutations  interact.  Using  this  data, 
heuristic approaches are most feasible allowing a starting point for future experiments. 
IDH1 
In  gliomas,  mutations  in  the  IDH1  gene  almost  always  result,  on  protein  level,  in  an 
arginine  to histidine  substitution at amino acid 132. (17)  In  this  thesis, we demonstrate 
that  in  glioma  alternative  mutations  affecting  codon  R132,  non‐R132H  mutation,  are 
more  frequent  in  astrocyomas  grade  III  and  oligoastrocytomas  grade  III  than  in 
oligodendrogliomas.  Furthermore,  these  non‐R132H mutations  are  frequently  found  in 
combination with TP53 mutations.   
Using the molecular classification, as described by Gravendeel et al, we do not observe a 
significant differential  segregation,  p=0.05, of  the  ratio of R132H/non‐R132H mutations 
between molecular subtypes 5/22 for Intrinsic glioma subtypes (IGS)‐17 and 1/27 for IGS‐
9.  (2,  9)  As  both  non‐R132H  and  R132H  mutations  are  found  in  the  same  molecular 


















    %  n  %  n  %  n  %  n  %  n  %  n 
IDH1                                        
R132  H  17%  18  22%  14  0%  0  53%  59  91%  1478  0%  0 
  C  46%  50  72%  46  100
% 
17  31%  35  5%  77  55%  12 
  G  19%  21  3%  2  0   0  8%  9  2%  34  32%  7 
  S  10%  11  2%  1  0%  0  4%  5  2%  27  5%  1 
  L  8%  9  2%  1  0%  0  4%  4  1%  13  9%  2 
  V                      0%  1      
   Total 
  
109     64     17     112     1630     22 
                                
IDH2                                     
R140  Q  0%  0  0%  0  0%  0  73%  122  0%*  0  **   
R172  K  0%  0  0%  0  0%  0  26%  44  60%  24  45%  5 
  M  17%  2  0%  0  0%  0  1%  1  23%  9  0%  0 
  W  0%  0  0%  0  0%  0  0%  0  13%  5  45%  5 
  G  8%  1  0%  0  0%  0  0%  0  5%  2  0%  0 
  S  75%  9  100
% 
2  0%  0  0%  0  0%  0  0%  0 
  N  0%  0  0   0  0%  0  0%  0  0%  0  9%  1 
    Total 
  










chapter  five:  functional  analysis  of  different  mutations.  One  could  investigate  with  a 
thorough  bioinformatical  analysis  if  multiple  mutations  are  associated,  in  different 
tumours, with gene expression or methylation patterns.  
Recently  an  IDH1‐R132H  conditional  knock‐in mouse model has been described. (18)  In 





IDH1  mutations.  (20)  Knock‐in  mice  do  not  develop  glial  brain  tumours,  and  the 




is  in  contrast  with  the  haematopoietic mouse model;  in  this model  an  increase  in  the 
number  of  precursor  cells  was  identified.  Since  the  double  negative  group  of  more 
differentiated cells contains neural‐restricted precursor cells, differentiated neurons, glial 
cells  and  some  endothelial  cells,  it  remains  possible  that  an  increase  in  the  number  of 
progenitor cells is present within one of these subsets of cells. This is specifically possible 
for  the  neural  restricted  precursor  cells  as  they  comprise  only  10%  of  the Nestin+  cell 
population.  The  differences  in  the  increase  in  number  of  progenitor  cells  between  the 
haematopoietic mouse model  and  the  brain model may  however  also  be  an  indication 
that the tumours initiate differently.  
Distribution of mutations amongst tumours 
IDH1  mutations  are  not  restricted  to  gliomas;  they  are  also  found  in  acute  myeloid 
leukemia  (AML),  Maffucci  syndrome  (MF)  and  Olliers  disease  (Oll)  (characterized  by 
multiple enchondromas, benign lesions mostly found in the bones of the hands and feet 
(21)) and  intrahepatic cholangiocarcinoma. When  looking  in detail at  IDH1 mutations  in 
these tumor types, we observe a tumour type specific mutation spectrum. The different 
mutation frequencies are highlighted in table 1 for codon R132 in IDH1 and codons R172 
and  R140  in  IDH2.  (22‐27)  For  example,  the  IDH1  R132C mutations  are  found  at  high 
frequency in AML whereas this mutation is rare in gliomas.  The R132C mutations are the 
most common mutation in MF and Oll. The R132H mutations are most frequent in glioma 
(91%)  whereas  in  Maffucci  syndrome  so  far  no  R132H  mutations  have  been  found. 
Although the number of Maffucci syndrome tumours is not very high, it is suggestive that 
not a single mutation has been found (p< 0.0001).   
It  is  not unique  for mutations  to be unevenly distributed between  tissues and within a 
tissue.  Using  the  COSMIC  database  (www.sanger.ac.uk),  we  observe  that  such  tumour 
type specific mutation pattern is also present in various other genes (table 2). In TP53 for 
  105 
example,  the  two most  frequent mutations occur at  the codons encoding  for R248 and 
R273. When we  look at  the number of mutations per  tissue  type we see  that  the  ratio 
between the two mutations for codon 248 is even whereas it is not for codon 273. There 





frequent  mutation  in  endometrial  cancer  whereas  the  ratio  in  gliomas  is  more  equal. 
(Fischer’s exact test, p=0.0013) 
 Different mutations  can  occur  due  to  external  factors,  the  best  known  example  is  the 
more  frequent  occurrence  of  G>A  transitions  in  non‐smokers  lung  cancers  whereas 
transversions G>T and G>C occur more  frequently  in  (former)  smokers.  (28)  In gliomas, 
the  treatment  with  an  alkylating  chemotherapy,  such  as  temozolamide,  results  in  G/T 
mismatches. (29) Such environmental factors can result  in a molecularly different tumor 
type.  For  example,  EGFR  is  known  to  be  frequently  mutated  in  lung  cancer,  but  the 
frequency  is  inversely  correlated with  smoking.  Looking  at mutations  in  EGFR exons 19 
and  21,  smokers  have  a  lower  frequency  of mutations  (4%)  compared  to  non‐smokers 
(51%). (30)  
To what  extent  the  different mutations  of  IDH1  and  the  difference  between  IDH1  and 
IDH2 is due to environmental changes or functional differences is unknown. It is however, 
quite  interesting  from a  functional perspective to determine this.  In  IDH1,  low frequent 
mutations such as G97D and R100A result in the increased concentration of 2HG, similar 
to  their more  frequent  cousin  (R132H).  It  remains  to  be  determined why  virtually  only 
Table 2. Frequency of different type of TP53 and PTEN mutations subdivided by tumour type.   TP53  p.R248  p.R273   c.743G>A  c.742C>T  c.817C>T  c.818G>A   p.R248Q  p.R248W  p.R273C  p.R273H 
Large intestine  131 (25%)  130 (28%)  98 (22%)  121 (24%) 
Breast  73 (14%)  57 (12%)  10 (2%)  62 (13%) 
CNS  35 (7%)  30 (6%)  110 (25%)  41 (8%) 
Glioma  29 (5%)  27 (6%)  106 (24%)  40 (8%) 
PNET/Medulloblastoma  6 (1%)  3 (1%)  4 (1%)  1 (<1%) 
Total*  534  465  441  496          
PTEN  p.R130G  p.R173  p.R233   c.388C>G  c.388C>T  c.389G>A  c.517C>T  c.518G>A  c.697C>T   p.R130G  p.R130*  p.R130Q  p.R173C  p.R173H  p.R233* 
Endometrium  66 (88%)  22 (39%)  38 (73%)  12 (40%)  2 (9%)  37 (55%) 
CNS  4 (5%)  21 (37%)  3 (6%)  16 (53%)  19 (83%)  11 (16%) 
Glioma  4 (5%)  19 (33%)  3 (6%)  16 (53%)  19  (83%)  11 (16%) 
PNET/Medulloblastoma  ‐  2 (4%)  ‐  ‐  ‐  ‐ 






R132H  mutations  occur. (31)  Functional  differences  could  indicate  that  IDH  mutations 
result  into more changes than  just an  increase  in 2HG. One way to do this would be to 
analyse the previously mentioned haematopoietic mouse model with an R132H mutation. 
It will be interesting to see whether other mutations (e.g.IDH1‐R132C, R140Q in IDH2) will 




codon  is  interesting  as  it  may  indicate  mutation  specific  functional  consequences.  An 
example of such mutation specific  functional consequences  is shown in chapter  five.    In 
this  chapter  we  have  studied  the  functional  consequences  of  different  activating 
mutations  in  EGFR.  In  GBMs,  the  most  common  mutation  identified  is  an  in  frame 





and  activate  a  different  transcription  response.  When  considering  pleiotropy,  multiple 
effects  by  a  single  gene,  it  is  perhaps  not  surprising  that  different mutations  result  in 
different  effects.  Other  groups  have  found  that  different  mutations  in  EGFR  are 
differently  associated with  DNA  repair  and  their  nuclear  translocation  is  different. (35) 
Also  for  TP53,  it  has  been  described  that  different  mutations  can  result  in  different 
binding partners, though only one of 15 interacting proteins was reported to result in an 
altered  function  resulting  in  increased  invasion.  (36)  So  although  a  mutation  can  be 
different  on  a  genomic  level  it  does  not  always  result  in  a  functional  difference  on  a 





In  this  thesis we have used various models  to  investigate brain tumours. We have used 
various  in  silico methods,  cell  lines  (both primary and established),  and mouse models. 
Models are imperfect; for example, to which extent current models vary from the original 
tumour  remains  to  be  detailed.  On  average  primary  cell  lines  resemble  tumours more 
than established lines, but only a subset of tumours can be propagated in vitro. E.g. IDH1 
mutations are gone after one to two rounds of cell culture. What is interesting to note, is 
that  when  primary  tumours  are  passed  on  as  xenografts,  IDH1  mutations  are 
retained. (13)  Primary  cell  lines  retain  intratumour  heterogeneity,  which  makes  them 
ideal  for  studying  a  human  tumour  but  makes  reproducibility  of  results  harder  and 
nessecitates an increase in number of experiments. Although genetic animal models can 
give valuable insight in a process,  identical mutations in mouse and man will not always 








patients  with  EGFR  mutations.  BRAF  inhibitors  have  increased  the  survival  of  patients 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In  this  thesis we  investigated both medulloblastoma and glioma. We have walked through the process of 
finding,  describing,  investigating  and  comparing  mutations.  We  have  looked  for  novel  mutations  in 
medulloblastoma, and we did functional research in glioma and looked into IDH1 and EGFR.  
In  chapter  one  we  have  investigated  ‘splicing’  in  medulloblastoma.  Based  on  gene  expression 
meduloblastoma  can  be  subdivided  in  four  distinct  groups,  WNT,  SHH,  group  3  and  group  4.  We  have 
looked in 117 samples for subgroup specific alterations and compared this with fetal brain tissue. We found 




In  chapters  three  and  four  we  further  examine  the  genetic  changes  of  IDH1.  In  the  third  chapter  we 
describe  that  apart  from  the most  frequent mutation,  IDH1  R132H,  other mutations  occur  on  the  same 
codon.  These mutations  are  not  normally  distributed  amongst  the  different  types  of  glioma.  These  non‐
R132H mutations occur more frequently in combination with mutations in TP53. On the other hand, loss of 
chromosomes  1p  and  19q,  a  frequent  occurance  in  oligodendroglioma,  is  inversely  correlated  with  the 
presence  of  these  non‐R132H mutations.  The  distribution  of  the  non‐R132H mutations  could  indicate  a 
different cause of the mutations, or a functional difference between these mutations. 
In the fourth chapter we are digging deeper into the function of the IDH1 R132H mutation. We show, that 
contrary  to  our  expectation,  cells  containing  this mutation  display  reduced  growth.  The  reduced  growth 
was  also observed when using  xenografts.  Staining  for  pAkt  in  these  cells  confirms  reduced activation  in 
these  cell  lines.  Patients  with  an  IDH1  mutation  have  an  increased  survival;  our  results  could  give  an 
indication why this could be. 
In chapter  five we compared different mutations of EGFR, EGFRvIII and EGFR L858R, with each other and 
compared  them  with  EGFR  wildtype.  EGFR L858R occurs  frequently  in  adenocarcinomas  of  the  lung, 
whereas the EGFRvIII mutation occurs most frequently in GBM. Inversly, EGFRvIII was never found in lung 
adenocarcinomas and EGFR L858R mutations were never  found  in GBM. This  is an  important  reason why 
we looked at these mutations, if there is a functional difference. Firstly we have used mass spectrometry to 
determine  whether  there  are  different  binding  partners  for  EGFR  or  its  mutants.   We  found  two  novel 
partners, DOCK4 and UGGT1. DOCK4 does not seem to be binding to EGFR L858R, but does however bind to 
EGFRvIII and EGFR wildtype. Furthermore, we see a strong difference in growth and migration between the 
different  variants  of  EGFR.  The  two  EGFR mutants  we  investigated,  EGFRvIII  and  EGFR  L858R,  display  a 














In  deze  thesis  hebben wij  basaal  onderzoek  gedaan naar medulloblastomen en  gliomen. We hebben het 










in  tumoren  en  van  ander  onderzoek  om  zodoende  een  basis  te  vormen  voor  verder  onderzoek.  In  dit 
hoofdstukken hebben wij verschillende aanknopingspunten voor verder onderzoek uitgewerkt.  
In de hoofdstukken vier en vijf gaan wij dieper  in op de genetische veranderingen van IDH1.  In hoofdstuk 
vier  beschrijven  wij  dat  er  naast  de  meest  voorkomende  mutatie,  IDH1  R132H,  andere  mutaties  op  dit 
codon voorkomen en dat deze niet normaal verdeeld zijn over de verschillende typen hersentumoren. Deze 
andere, oftewel de niet‐R132H mutaties, komen voornamelijk voor in tumoren met een mutatie in het gen 
TP53,  dit  zijn  vaker  astrocytomen. Daarentegen  komen wij  deze mutatie  relatief weinig  tegen  als  er  een 




Wij  laten  zien  dat,  tegen  onze  verwachting  in,  cellen  met  deze  mutatie  langzamer  groeien  wanneer  er 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